320 results on '"Oldroyd, K"'
Search Results
2. Storied Lessons: Learning from Anger in Childhood by Narrating
- Author
-
Pasupathi, M., Wainryb, C., Oldroyd, K., and Bourne, S.
- Abstract
We evaluated whether narrating anger-provoking events promoted learning from those events, as compared with other responses to anger, and whether the effectiveness of narrative depended on age. In addition, we tested relations between anger reduction and learning and, in a subset of participants, between narrative quality and learning. A sample of 248 young people (eight to 17 years old) recalled an anger-provoking experience and were randomly assigned to one of four activities: recalling the event a second time; narrating the event; and distraction (via video game play or conversation). The young people then recalled the event one last time, and rated the extent to which they had learned from that event. Younger children reported more learning when they had narrated their experience. Youths reported more learning when they had narrated the event more frequently prior to participation. Stronger reductions in anger following regulation were associated with greater self-reported learning. Finally, more elaborative and less resolved narratives were associated with greater self-reported learning.
- Published
- 2019
- Full Text
- View/download PDF
3. Improvement in angina pectoris after percutaneous coronary interventions in focal and diffuse coronary artery disease
- Author
-
Munhoz, D, primary, Collet, C, additional, Collison, D, additional, Mizukami, T, additional, McCartney, P, additional, Sonck, J, additional, Ford, T, additional, Berry, C, additional, De Bruyne, B, additional, and Oldroyd, K, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Modelling the Impact of Atherosclerosis on Drug Release and Distribution from Coronary Stents
- Author
-
McKittrick, C. M., Kennedy, S., Oldroyd, K. G., McGinty, S., and McCormick, C.
- Published
- 2016
- Full Text
- View/download PDF
5. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial
- Author
-
Geuns, R.J.M. van, Chun-Chin, Chang, McEntegart, Margaret B., Merkulov, E., Kretov, Evgeny, Lesiak, M., Onuma, Yoshinobu, Oldroyd, K., Geuns, R.J.M. van, Chun-Chin, Chang, McEntegart, Margaret B., Merkulov, E., Kretov, Evgeny, Lesiak, M., Onuma, Yoshinobu, and Oldroyd, K.
- Abstract
Item does not contain fulltext
- Published
- 2022
6. Fractional Flow Reserve–Based Coronary Artery Bypass Surgery: Current Evidence and Future Directions
- Author
-
Spadaccio, C., Glineur, D., Barbato, E., Di Franco, A., Oldroyd, K. G., Biondi-Zoccai, G., Crea, Filippo, Fremes, S. E., Angiolillo, D. J., Gaudino, Mario Fulvio Luigi, Spadaccio, C., Glineur, D., Barbato, E., Di Franco, A., Oldroyd, K. G., Biondi-Zoccai, G., Crea, F., Fremes, S. E., Angiolillo, D. J., and Gaudino, M.
- Subjects
Cardiac Catheterization ,Coronary Artery Bypa ,Predictive Value of Test ,Coronary Artery Disease ,Coronary Angiography ,Fractional Flow Reserve ,FFR ,Article ,Fractional Flow Reserve, Myocardial ,surgical procedures, operative ,Treatment Outcome ,Predictive Value of Tests ,myocardial revascularization ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,Myocardial ,Humans ,Coronary Artery Bypass ,CABG ,Vascular Patency ,Human - Abstract
Fractional flow reserve (FFR) provides an objective measurement of the severity of ischemia caused by coronary stenoses in downstream myocardial regions. Data from the interventional cardiology realm have suggested benefits of a FFR-guided percutaneous coronary intervention (PCI) strategy. Limited evidence is available on the use of FFR to guide coronary artery bypass grafting (CABG). The most recent data have shown that FFR might simplify CABG procedures and optimize patency of arterial grafts without any clear impact on clinical outcomes. The aim of this review is to summarize the available data on FFR-based CABG and discuss the rationale and potential consequences of a switch towards FFR-based surgical revascularization strategy.
- Published
- 2020
7. Comparison of risk prediction models in infarct-related cardiogenic shock
- Author
-
Freund, A, primary, Poess, J, additional, De Waha-Thiele, S, additional, Meyer-Saraei, R, additional, Fuernau, G, additional, Zeymer, U, additional, Feistritzer, H J, additional, Rubini, M, additional, Oldroyd, K, additional, Windecker, S, additional, Montalescot, G, additional, Schneider, S, additional, Baran, D, additional, Desch, S, additional, and Thiele, H, additional
- Published
- 2021
- Full Text
- View/download PDF
8. OC 20 - DEVELOPMENT OF MIRNA ELUTING STENTS
- Author
-
Stepto, H., Dakin, R., Mcdonald, R., Kennedy, S., Cronin, L., Oldroyd, K., and Baker, A.
- Published
- 2015
9. A randomised, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI: The CAMPFIRE (CArdiac Muscle Preservation Following Ischemia REperfusion) Study
- Author
-
Adlam, D, Uren, N, Oldroyd, K, Munir, S, Sharp, A, Zaman, A, Contractor, H, Kiss, R, Edes, I, Jr, ZM, Garcia, MJ, Musialek, P, Tomcsanyi, J, Ptaszynski, P, Nagy, G, Szachniewicz, J, Siegel, L, Shirodaria, C, Selvanayagam, JB, Tulloch, S, Investigators, Campfire, and Channon, KM
- Published
- 2020
- Full Text
- View/download PDF
10. Intravascular imaging and 12-month mortality after unprotected left main stem PCI: an analysis of 11,624 cases from British Cardiovascular Intervention Society database
- Author
-
Tim, K, Tom, J, Anderson, R, Gallagher, S, Sirker, A, Debleder, M, Ludman, P, Oldroyd, K, Banning, A, Mamas, M, and Curzen, N
- Subjects
R735 ,RC666 ,R1 - Abstract
Background: Limited registry data supports the use of intravascular imaging during unprotected left main-stem PCI (uLMS-PCI) to improve outcomes. We used the BCIS national PCI database to explore temporal changes in the use of intravascular imaging for uLMS-PCI, defined the associates of imaging use, and correlate clinical outcomes including survival with imaging use.\ud \ud Methods: Data were analysed from 11,264 uLMS-PCI procedures performed in England and Wales between 2007 and 2014. Multivariate logistic regression was used to identify associates of imaging use. Propensity matching created 5,056 pairs of subjects with and without imaging, and logistic regression performed to quantify the association between imaging and outcomes. Multivariate logistic regression to identify the independent predictors of 12-month mortality was performed.\ud \ud Results: Imaging use increased from 30.2% in 2007 to 50.2% in 2014 (p
- Published
- 2020
11. One-Year Outcomes after PCI Strategies in Cardiogenic Shock
- Author
-
Thiele, H, Akin, I, Sandri, M, de Waha-Thiele, S, Meyer-Saraei, R, Fuernau, G, Eitel, I, Nordbeck, P, Geisler, T, Landmesser, U, Skurk, C, Fach, A, Jobs, A, Lapp, H, Piek, JJ, Noc, M, Goslar, T, Felix, SB, Maier, LS, Stepinska, J, Oldroyd, K, Serpytis, P, Montalescot, G, Barthelemy, O, Huber, K, Windecker, S, Hunziker, L, Savonitto, S, Torremante, P, Vrints, C, Schneider, S, Zeymer, U, Desch, S, Investigators, CULPRIT-SHOCK, Mamas, MA, Cardiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and CULPRIT-SHOCK Investigators
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Infarction ,610 Medicine & health ,030204 cardiovascular system & hematology ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,030212 general & internal medicine ,Myocardial infarction ,cardiovascular diseases ,business.industry ,Cardiogenic shock ,R735 ,Percutaneous coronary intervention ,General Medicine ,RC666 ,medicine.disease ,R1 ,Heart failure ,Conventional PCI ,Cardiology ,Myocardial infarction complications ,Human medicine ,business ,RA ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Item does not contain fulltext BACKGROUND: Among patients with acute myocardial infarction, cardiogenic shock, and multivessel coronary artery disease, the risk of a composite of death from any cause or severe renal failure leading to renal-replacement therapy at 30 days was found to be lower with percutaneous coronary intervention (PCI) of the culprit lesion only than with immediate multivessel PCI. We evaluated clinical outcomes at 1 year. METHODS: We randomly assigned 706 patients to either culprit-lesion-only PCI or immediate multivessel PCI. The results for the primary end point of death or renal-replacement therapy at 30 days have been reported previously. Prespecified secondary end points at 1 year included death from any cause, recurrent myocardial infarction, repeat revascularization, rehospitalization for congestive heart failure, the composite of death or recurrent infarction, and the composite of death, recurrent infarction, or rehospitalization for heart failure. RESULTS: As reported previously, at 30 days, the primary end point had occurred in 45.9% of the patients in the culprit-lesion-only PCI group and in 55.4% in the multivessel PCI group (P=0.01). At 1 year, death had occurred in 172 of 344 patients (50.0%) in the culprit-lesion-only PCI group and in 194 of 341 patients (56.9%) in the multivessel PCI group (relative risk, 0.88; 95% confidence interval [CI], 0.76 to 1.01). The rate of recurrent infarction was 1.7% with culprit-lesion-only PCI and 2.1% with multivessel PCI (relative risk, 0.85; 95% CI, 0.29 to 2.50), and the rate of a composite of death or recurrent infarction was 50.9% and 58.4%, respectively (relative risk, 0.87; 95% CI, 0.76 to 1.00). Repeat revascularization occurred more frequently with culprit-lesion-only PCI than with multivessel PCI (in 32.3% of the patients vs. 9.4%; relative risk, 3.44; 95% CI, 2.39 to 4.95), as did rehospitalization for heart failure (5.2% vs. 1.2%; relative risk, 4.46; 95% CI, 1.53 to 13.04). CONCLUSIONS: Among patients with acute myocardial infarction and cardiogenic shock, the risk of death or renal-replacement therapy at 30 days was lower with culprit-lesion-only PCI than with immediate multivessel PCI, and mortality did not differ significantly between the two groups at 1 year of follow-up. (Funded by the European Union Seventh Framework Program and others; CULPRIT-SHOCK ClinicalTrials.gov number, NCT01927549 .).
- Published
- 2018
- Full Text
- View/download PDF
12. Recovery of normal diurnal variation of blood pressure following renal artery stenting
- Author
-
Balachandran, K P and Oldroyd, K G
- Published
- 2003
- Full Text
- View/download PDF
13. Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey
- Author
-
Adamo, Marianna, Byrne, Robert A., Baumbach, Andreas, Haude, Michael, Windecker, Stephan, Valgimigli, Marco, Aaroe, J., Abdeltawab, A. A., Accardi, R., Addad, F., Agostoni, P., Alajab, A., Alcázar, E., Alhabil, B., Altug Cakmak, H., Amico, F., Amoroso, G., Anderson, R., Andò, G., Andreou, A. Y., Antoniadis, D., Aquilina, M., Aramberry, L., Auer, J., Auffret, V., Ausiello, A., Austin, D., Avram, A., Ayman, E., Babunashvili, V., Bagur, R., Bakotic, Z., Balducelli, M., Ballesteros, S. M., Baptista, S., Baranauskas, A., Barbeau, G., Bax, M., Benchimol, C., Berroth, R., Biasco, L., Bilal, A., Binias, K., Blanco Mata, R., Boccuzzi, G., Bolognese, L., Boskovic, S., Bourboulis, N., Briguori, C., Bunc, M., Buysschaert, I., Calabro’, P., Campo, G., Candiello, A., Caprotta, U. F., Cardenas, M., Carrilho-Ferreira, P., Carrizo, S., Caruso, M., Cassar, A., Cernigliaro, C., Chacko, G., Chamie, D., Clapp, B., Coceani, M., Colangelo, S., Colombo, A., Comeglio, M., Connaughton, M., Conway, D., Cortese, B., Cosgrave, J., Costa, F., Couvoussis, E., Crimi, G., Crook, R., Cruz-Alvarado, J. E., Curello, S., D’Ascenzo, F., D’Urbano, M., Dana, A., De Backer, O., De Carlo, M., De Cesare, N., De Iaco, G., De La Torre, H. J. M., De Oliveira Netoj, B., Devlin, G. P., Di Lorenzo, E., Díaz, A., Dina, C., Dorsel, T. H., Eberli, F. R., Echeverría, R., Eftychiou, C., Elguindy, A., Ercilla, J., Ernst, A., Esposito, G., Ettori, F., Eufracino, Null, Ezquerra Aguilera, W., Falcone, C., Falu, R. M., Feres, F., Ferlini, M., Fernández, G., Fernández-Rodríguez, D., Fileti, L., Fischetti, D., Florescu, N., Formigli, D., Fouladvand, F., Franco, N., Fresco, C., Frigoli, E., Furmaniuk, J., Gabaldo, K., Galli, M., Galli, S., Garbo, R., Garducci, S., Garg, S., Gavrielatos, G., Gensch, J., Giacchi, G., Giunio, L., Giustino, G., Goldberg, L., Goldsmit, R., Gommeaux, A., González Godínez, H., Gosselin, G., Govorov, A., Grimfjard, P., Gross, E., Grosz, C., Guagliumi, G., Hadad, W., Hadadi, L., Hansen, P. R., Harb, S., Hatrick, R., Hayrapetyan, H. G., Hernández-Enríquez, M., Ho Heo, J., Horvath, I. G., Huan Loh, P., Ibrahim, A. M., Ierna, S., Ilic, I., Imperadore, F., Ionescu-Silva, E., Jacksch, R., James, S., Janiak, B., Jensen, S. E., Jeroen, S., Jugessur, R. K., Kala, P., Kambis, M., Kanakakis, J., Karamasis, G., Karchevsky, D., Karpovskiy, A., Kayaert, P., Kedev, S., Kemala, E., Ketteler, T., Khan, S. Q., Kharlamov, A., Kiernan, T., Kiviniem, T., Koltowski, L., Koskinas, K. C., Kouloumpinis, A., Kraaijeveld, A. O., Krizanic, F., Krötz, B., Kuczmik, W., Kukreja, N., Kuksa, D., Yav, K., Kyriakos, D., Labrunie, A., Laine, M., Lapin, O., Larosa, C., Latib, A., Lattuca, B., Lauer, B., Lefèvre, T., Legrand, V., Lehto, P., Leiva-Pons, J. L., Leone, A. M., Lev, G., Lim, R., Limbruno, U., Linares Vicente, J. A., Lindsay, S., Linnartz, C., Liso, A., Lluberas, R., Locuratolo, N., Lokshyn, S., Lunde, K., Lupi, A., Magnavacchi, P., Maia, F., Mainar, V., Mancone, M., Manolios, M. G., Mansour, S., Mariano, E., Marques, K., Martins, H., Mckenzie, D., Meco, S., Meemook, K., Mehmed, K., Melikyan, A., Mellwig, K. P., Mendiz, O. A., Merkulov, E., Mesquita, H. G., Mezzapelle, G., Miloradovic, V., Mohamed, S., Mohammed, B., Mohammed, F., Mohammed, K., Mohanad, A., Morawiec, B., More, R., Moreno-Martínez, F. L., Mrevlje, B., Muhammad, F., Näveri, H., Nazzaro, M. S., Neary, P., Negus, B. H., Nelson Durval, F. G., Nick, H., Nilva, E., Oldroyd, K. G., Olivares Asencio, C., Omerovic, E., Ortiz, M. A., Ota, H., Otasevic, P., Otieno, H. A., Paizis, I., Papp, E., Pasquetto, G., Patsourakos, N. G., Peels, J., Pelliccia, F., Pennacchi, M., Penzo, C., Perez, P., Perkan, A., Petrou, E., Phipathananunth, W., Pierri, A., Pinheiro, L. F., Pipa, J. L., Piva, T., Polad, J., Porto, I., Poveda, J., Predescu, L., Prog, R., Puri, R., Raco, D. L., Ramazan, O., Ramazzotti, V., Rao, S. V., Raungaard, B., Reczuch, K., Rekik, S., Rhouati, A., Rigattieri, S., Rodríguez-Olivares, R., Roik, M., Romagnoli, E., Román, A. J., Routledge, H., Rubartelli, P., Rubboli, A., Ruiz-García, J., Russo, F., Ruzsa, Z., Ryding, A., Saad, Aly, Sabate, M., Sabouret, P., Sadowski, M., Saia, F., Sanchez Perez, I., Santoro, G. M., Sarenac, D., Saririan, M., Sarma, J., Schuetz, T., Sciahbasi, A., Sebastian, M., Sebik, R., Sesana, M., Hur, Seung-Ho, Sganzerla, P., Shalva, R., Sharma, S., Sheiban, I., Shein, K. K., Shiekh, I. A., Sinha, M., Slhessarenko, J., Smith, D., Smyth, D. W., Sönmez, K., Sood, N., Sourgounis, A., Srdanovic, I., Stables, R. H., Stefanini, G. G., Stewart, J., Stoyanov, N., Suliman, A. A., Suryadevara, R., Suwannasom, P., Tange Veien, K., Tauchert, S., Tebet, M., Testa, L., Thury, A., Tilsted, H. H., Tiroch, K., Torres, A., Tosi, P., Traboulsi, M., Trani, C., Tresoldi, S., Tsigkas, G., Tueller, D., Turri, M., Udovichenko, A. E., Uretsky, B., Van Der Harst, P., Van Houwelingen, K. G., Vandoni, P., Vandormael, M., Varbella, F., Venkitachalam, C. G., Vercellino, M., Vidal-Perez, R., Vigna, C., Vignali, L., Vogt, F., Voudris, V., Vranckx, P., Vrolix, M., Vydt, T., Webster, M., Wijns, W., Woody, W., Wykrzykowska, J., Yazdani, S., Yildiz, A., Yurlevich, D., Zauith, R., Zekanovic, D., Zhao, M., Zimarino, M., Zingarelli, A., Abdelsamad, A. Y., Abo Shaera, E. S., Afshar, M. S., Agatiello, C., Aguiar, P., Ahmad, A. M., Akin, I., Alameda, M., Alegría-Barrero, E., Alejos, R., Alkhashab, K., Alkutshan, R. S. A., Almorraweh, A., Altnji, I., Alvarez Iorio, C., Anchidin, O., Angel, J., Antonopoulos, A., Apshilava, G., Arana, C., Ashikaga, T., Assomull, R., Atef, S. Z., Azmus, A. D., Azzalini, L., Azzouz, A., Baglioni, P., Bampas, G., Basil, M. P., Baumbach, A., Besh, D., Bhushan Sharm, A., Bien Hsien, H., Bihui, L., Bing-Chen, L., Biryukov, S., Blatt, A., Bocchi, E., Boghdady, A., Bonarjee, V. V. S., Bosnjak, I., Bravo Baptista, S., Brinckman, S. L., Buchter, B., Burzotta, F., Cacucci, M., Cagliyan, C. E., Calabrò, P., Cernetti, C., Chávez Mizraym, R., Choo, W. S., Choudhury, R., Cicco, N., Cisneros Clavijo, P., Çitaku, H., Collet, J. P., Consuegra-Sánchez, L., Conte, M., Corral, J. M., Damonte, A., Dangoisse, V., Dastani, M., Della Rosa, F., Deora, S., Devadathan, S., Dharma, S., Di Giorgio, A., Diez, J. L., Dinesha, B., Duplančić, D., El Behwashi, M. F., Elghawaby, H., Elshahawy, O., Eskola, M. J., Etman, A., Eun Gyu, L., Fabiano, L., Facta, A., Fan, Y., Fang-Yang, H., Farag, E., Fathi, Y., Fazeli, N., Federico, P., Fereidoun, M. Z., Fernandez-Nofrerias, E., Flensted Lassen, J., Flessas, D., Fouad, H., Franco-Pelaez, J. A., Fu, Q., Furtado, R., Gadepalli, R., Gallino, R., Gasparetto, V., Gentiletti, A., Gholoobi, A., Ghosh, A. K., Gkizas, S., Golchha, S. K., Goncharov, A., Gössl, M., Götberg, M., Greco, F., Grundeken, M. J., Gupta, D., Gupta, S., Guray, U., Hahalis, G., Hakim Vista, J., Hamid, M. A., Hammoudeh, A., Hasan, A. R. I., Hatsumura, F. E., Heintzen, M. P., Helal, T., Hetherington, S., Hewarathna, U. I., Hioki, H., Hissein, F., Ho-Ping, Y., Homs, S., Huber, K., Ibarra, F. M., Ielasi, A., Ipek, E., Jambunathan, R., Jamshidi, P., Jarrad, I., Javier, W., Jensen, J., Jimenez-Quevedo, P., Kalpak, O., Kan, J., Kanaan, T., Kao, D. H. M., Karamfiloff, K., Karegren, A., Karjalainen, P. P., Kasabov, R., Katsimagklis, G. D., Kaul, U., Khan, A., Kiemeneij, E., Kiviniemi, T., Kleiban, A., Komiyama, N., Konteva, M., Koshy, G., Krepsky, A. M., Kuljit, S., Kulkarni, P., Kumar, V., Kuznetsov, I., Lai, G., Lateef, M. A., Lawand, S., Le Hong, T., Lettieri, C., Levy, G., Lindvall, P., Maitra, A., Makowski, M., Mamas, M. A., Mandal, S. C., Mangalanandan, P., Marin, R., Mashhadi, M., Matsukage, T., Meier, B., Milosavljevic, B., Miro, S. S., Mitov, A., Moeriel, M., Moguel, R., Mohanty, A., Montalescot, G., Mörsdorf, W., Moscato, F., Muniz, A., Muraglia, S., Myć, J., Nada, A., Nair, P., Namazi, M. H., Naraghipour, F., Nguyen, Q. N., Nicosia, A., Nikas, D., Ober, M., Ocaranza-Sánchez, R., Olivecrona, G., Pahlajani, D., Pandey, B. P., Parma, A., Parma, R., Patsilinakos, S. P., Pattam, J., Peddi, S., Perez, P. R., Peruga, J. Z., Pescoller, F., Petrov, I., Piatti, L., Pico-Aracil, F., Pina, J., Piroth, Z., Popa, V., Pourbehi, M. R., Pradhan, A. K., Prida, X. E., Purohit, B. V., Pyun, W. B., Quang Hung, D., Rada, I., Rafizadeh, O., Rahman, M. A., Rai, L., Ramsewak, A., Ravindran, R., Rodriguez De Leiras, O. S., Rodríguez Esteban, M., Roque Figueira, H., Saket, A., Sakhov, O., Saktheeswaran, M. K., Salachas, A., Sallam, A., Sampaolesi, A., Samy, A., Sanchis, J., Santaera, O., Santarelli, A., Santharaj, W. S., Sarango, B., Satheesh, S., Schmitz, T., Schühlen, H., Seewoosagur, R., Segev, A., Seisembekov, V., Semitko, S., Sengottuvelu, G., Sepulveda Varela, P., Sethi, A., Sharma, A., Sharma, R. K., Shi, Hy., Şimşek, M. A., Siqueira, B., Skalidis, E., Slawin, J., Sorokhtey, L., Spaulding, C., Srinivas, B., Srinivasan, M., Stakos, D., Stefanini, G., Stojkovic, S., Tacoy, G., Tawade, M., Tiecco, F., Tondi, S., Torresani, E. M., Tousek, P., Tran, T., Trantalis, G., Triantafyllou, K., Trivedi, R., Trivisonno, A., Tsui, K. L., Türkoğlu, C., Tzung-Dau, W., Ueno, H., Urban, U., Uretsky, B. F., Uscumlic, A., Venugopal, V., Verney, R., Vilar, J. V., Villacorta, V. G., Vishwanath, R., Vlachojannis, G. J., Vlachojannis, M., Vlad, V., Von Birgelen, C., Vukcevic, V., Wahab, A., Waksman, R., Wei-Wen, L., Weisz, G., Whittaker, A., Yadav, A., Yokoi, Y., Zacharoulis, A., Zahran, M., Zamani, J., Ziakas, A., Zimmermann, J. P., Adamo, M., Byrne, R. A., Baumbach, A., Haude, M., Windecker, S., Valgimigli, M., Aaroe, J., Abdeltawab, A. A., Accardi, R., Addad, F., Agostoni, P., Alajab, A., Alcazar, E., Alhabil, B., Altug Cakmak, H., Amico, F., Amoroso, G., Anderson, R., Ando, G., Andreou, A. Y., Antoniadis, D., Aquilina, M., Aramberry, L., Auer, J., Auffret, V., Ausiello, A., Austin, D., Avram, A., Ayman, E., Babunashvili, V., Bagur, R., Bakotic, Z., Balducelli, M., Ballesteros, S. M., Baptista, S., Baranauskas, A., Barbeau, G., Bax, M., Benchimol, C., Berroth, R., Biasco, L., Bilal, A., Binias, K., Blanco Mata, R., Boccuzzi, G., Bolognese, L., Boskovic, S., Bourboulis, N., Briguori, C., Bunc, M., Buysschaert, I., Calabro', P., Campo, G., Candiello, A., Caprotta, U. F., Cardenas, M., Carrilho-Ferreira, P., Carrizo, S., Caruso, M., Cassar, A., Cernigliaro, C., Chacko, G., Chamie, D., Clapp, B., Coceani, M., Colangelo, S., Colombo, A., Comeglio, M., Connaughton, M., Conway, D., Cortese, B., Cosgrave, J., Costa, F., Couvoussis, E., Crimi, G., Crook, R., Cruz-Alvarado, J. E., Curello, S., D'Ascenzo, F., D'Urbano, M., Dana, A., De Backer, O., De Carlo, M., De Cesare, N., De Iaco, G., De La Torre, H. J. M., De Oliveira Netoj, B., Devlin, G. P., Di Lorenzo, E., Diaz, A., Dina, C., Dorsel, T. H., Eberli, F. R., Echeverria, R., Eftychiou, C., Elguindy, A., Ercilla, J., Ernst, A., Esposito, G., Ettori, F., Eufracino, Ezquerra Aguilera, W., Falcone, C., Falu, R. M., Feres, F., Ferlini, M., Fernandez, G., Fernandez-Rodriguez, D., Fileti, L., Fischetti, D., Florescu, N., Formigli, D., Fouladvand, F., Franco, N., Fresco, C., Frigoli, E., Furmaniuk, J., Gabaldo, K., Galli, M., Galli, S., Garbo, R., Garducci, S., Garg, S., Gavrielatos, G., Gensch, J., Giacchi, G., Giunio, L., Giustino, G., Goldberg, L., Goldsmit, R., Gommeaux, A., Gosselin, G., Govorov, A., Gonzalez Godinez, H., Gross, E., Grosz, C., Guagliumi, G., Hadad, W., Hadadi, L., Hansen, P. R., Harb, S., Hatrick, R., Hayrapetyan, H. G., Hernandez-Enriquez, M., Ho Heo, J., Horvath, I. G., Huan Loh, P., Ibrahim, A. M., Ierna, S., Ilic, I., Imperadore, F., Ionescu-Silva, E., Jacksch, R., James, S., Janiak, B., Jensen, S. E., Jeroen, S., Jugessur, R. K., Kala, P., Kambis, M., Kanakakis, J., Karamasis, G., Karchevsky, D., Karpovskiy, A., Kayaert, P., Kedev, S., Kemala, E., Ketteler, T., Khan, S. Q., Kharlamov, A., Kiernan, T., Kiviniem, T., Koltowski, L., Koskinas, K. C., Kouloumpinis, A., Kraaijeveld, A. O., Krizanic, F., Krotz, B., Kuczmik, W., Kukreja, N., Kuksa, D., Yav, K., Kyriakos, D., Labrunie, A., Laine, M., Lapin, O., Larosa, C., Latib, A., Lattuca, B., Lauer, B., Lefevre, T., Legrand, V., Lehto, P., Leiva-Pons, J. L., Leone, A. M., Lev, G., Lim, R., Limbruno, U., Linares Vicente, J. A., Lindsay, S., Linnartz, C., Liso, A., Lluberas, R., Locuratolo, N., Lokshyn, S., Lunde, K., Lupi, A., Magnavacchi, P., Maia, F., Mainar, V., Mancone, M., Manolios, M. G., Mansour, S., Mariano, E., Marques, K., Martins, H., Mckenzie, D., Meco, S., Meemook, K., Mehmed, K., Melikyan, A., Mellwig, K. P., Mendiz, O. A., Merkulov, E., Mesquita, H. G., Mezzapelle, G., Miloradovic, V., Mohamed, S., Mohammed, B., Mohammed, F., Mohammed, K., Mohanad, A., Morawiec, B., More, R., Moreno-Martinez, F. L., Mrevlje, B., Muhammad, F., Naveri, H., Nazzaro, M. S., Neary, P., Negus, B. H., Nelson Durval, F. G., Nick, H., Nilva, E., Oldroyd, K. G., Olivares Asencio, C., Omerovic, E., Ortiz, M. A., Ota, H., Otasevic, P., Otieno, H. A., Paizis, I., Papp, E., Pasquetto, G., Patsourakos, N. G., Peels, J., Pelliccia, F., Pennacchi, M., Penzo, C., Perez, P., Perkan, A., Petrou, E., Phipathananunth, W., Pierri, A., Pinheiro, L. F., Pipa, J. L., Piva, T., Polad, J., Porto, I., Poveda, J., Predescu, L., Prog, R., Puri, R., Raco, D. L., Ramazan, O., Ramazzotti, V., Rao, S. V., Raungaard, B., Reczuch, K., Rekik, S., Rhouati, A., Rigattieri, S., Rodriguez-Olivares, R., Roik, M., Romagnoli, E., Roman, A. J., Routledge, H., Rubartelli, P., Rubboli, A., Ruiz-Garcia, J., Russo, F., Ruzsa, Z., Ryding, A., Saad, A., Sabate, M., Sabouret, P., Sadowski, M., Saia, F., Sanchez Perez, I., Santoro, G. M., Sarenac, D., Saririan, M., Sarma, J., Schuetz, T., Sciahbasi, A., Sebastian, M., Sebik, R., Sesana, M., Hur, S. -H., Sganzerla, P., Shalva, R., Sharma, S., Sheiban, I., Shein, K. K., Shiekh, I. A., Sinha, M., Slhessarenko, J., Smith, D., Smyth, D. W., Sonmez, K., Sood, N., Sourgounis, A., Srdanovic, I., Stables, R. H., Stefanini, G. G., Stewart, J., Stoyanov, N., Suliman, A. A., Suryadevara, R., Suwannasom, P., Tange Veien, K., Tauchert, S., Tebet, M., Testa, L., Thury, A., Tilsted, H. H., Tiroch, K., Torres, A., Tosi, P., Traboulsi, M., Trani, C., Tresoldi, S., Tsigkas, G., Tueller, D., Turri, M., Udovichenko, A. E., Uretsky, B., Van Der Harst, P., Van Houwelingen, K. G., Vandoni, P., Vandormael, M., Varbella, F., Venkitachalam, C. G., Vercellino, M., Vidal-Perez, R., Vigna, C., Vignali, L., Vogt, F., Voudris, V., Vranckx, P., Vrolix, M., Vydt, T., Webster, M., Wijns, W., Woody, W., Wykrzykowska, J., Yazdani, S., Yildiz, A., Yurlevich, D., Zauith, R., Zekanovic, D., Zhao, M., Zimarino, M., Zingarelli, A., Abdelsamad, A. Y., Abo Shaera, E. S., Afshar, M. S., Agatiello, C., Aguiar, P., Ahmad, A. M., Akin, I., Alameda, M., Alegria-Barrero, E., Alejos, R., Alkhashab, K., Alkutshan, R. S. A., Almorraweh, A., Altnji, I., Alvarez Iorio, C., Anchidin, O., Angel, J., Antonopoulos, A., Apshilava, G., Arana, C., Ashikaga, T., Assomull, R., Atef, S. Z., Azmus, A. D., Azzalini, L., Azzouz, A., Baglioni, P., Bampas, G., Basil, M. P., Besh, D., Bhushan Sharm, A., Bien Hsien, H., Bihui, L., Bing-Chen, L., Biryukov, S., Blatt, A., Bocchi, E., Boghdady, A., Bonarjee, V. V. S., Bosnjak, I., Bravo Baptista, S., Brinckman, S. L., Buchter, B., Burzotta, F., Cacucci, M., Cagliyan, C. E., Cernetti, C., Chavez Mizraym, R., Choo, W. S., Choudhury, R., Cicco, N., Cisneros Clavijo, P., Citaku, H., Collet, J. P., Consuegra-Sanchez, L., Conte, M., Corral, J. M., Damonte, A., Dangoisse, V., Dastani, M., Della Rosa, F., Deora, S., Devadathan, S., Dharma, S., Di Giorgio, A., Diez, J. L., Dinesha, B., Duplancic, D., El Behwashi, M. F., Elghawaby, H., Elshahawy, O., Eskola, M. J., Etman, A., Eun Gyu, L., Fabiano, L., Facta, A., Fan, Y., Fang-Yang, H., Farag, E., Fathi, Y., Fazeli, N., Federico, P., Fereidoun, M. Z., Fernandez-Nofrerias, E., Flensted Lassen, J., Flessas, D., Fouad, H., Franco-Pelaez, J. A., Fu, Q., Furtado, R., Gadepalli, R., Gallino, R., Gasparetto, V., Gentiletti, A., Gholoobi, A., Ghosh, A. K., Gkizas, S., Golchha, S. K., Goncharov, A., Gossl, M., Gotberg, M., Greco, F., Grundeken, M. J., Gupta, D., Gupta, S., Guray, U., Hahalis, G., Hakim Vista, J., Hamid, M. A., Hammoudeh, A., Hasan, A. R. I., Hatsumura, F. E., Heintzen, M. P., Helal, T., Hetherington, S., Hewarathna, U. I., Hioki, H., Hissein, F., Ho-Ping, Y., Homs, S., Huber, K., Ibarra, F. M., Ielasi, A., Ipek, E., Jambunathan, R., Jamshidi, P., Jarrad, I., Javier, W., Jensen, J., Jimenez-Quevedo, P., Kalpak, O., Kan, J., Kanaan, T., Kao, D. H. M., Karamfiloff, K., Karegren, A., Karjalainen, P. P., Kasabov, R., Katsimagklis, G. D., Kaul, U., Khan, A., Kiemeneij, E., Kiviniemi, T., Kleiban, A., Komiyama, N., Konteva, M., Koshy, G., Krepsky, A. M., Kuljit, S., Kulkarni, P., Kumar, V., Kuznetsov, I., Lai, G., Lateef, M. A., Lawand, S., Le Hong, T., Lettieri, C., Levy, G., Lindvall, P., Maitra, A., Makowski, M., Mamas, M. A., Mandal, S. C., Mangalanandan, P., Marin, R., Mashhadi, M., Matsukage, T., Meier, B., Milosavljevic, B., Miro, S. S., Mitov, A., Moeriel, M., Moguel, R., Mohanty, A., Montalescot, G., Morsdorf, W., Moscato, F., Muniz, A., Muraglia, S., Myc, J., Nada, A., Nair, P., Namazi, M. H., Naraghipour, F., Nguyen, Q. N., Nicosia, A., Nikas, D., Ober, M., Ocaranza-Sanchez, R., Olivecrona, G., Pahlajani, D., Pandey, B. P., Parma, A., Parma, R., Patsilinakos, S. P., Pattam, J., Peddi, S., Perez, P. R., Peruga, J. Z., Pescoller, F., Petrov, I., Piatti, L., Pico-Aracil, F., Pina, J., Piroth, Z., Popa, V., Pourbehi, M. R., Pradhan, A. K., Prida, X. E., Purohit, B. V., Pyun, W. B., Quang Hung, D., Rada, I., Rafizadeh, O., Rahman, M. A., Rai, L., Ramsewak, A., Ravindran, R., Rodriguez De Leiras, O. S., Rodriguez Esteban, M., Roque Figueira, H., Saket, A., Sakhov, O., Saktheeswaran, M. K., Salachas, A., Sallam, A., Sampaolesi, A., Samy, A., Sanchis, J., Santaera, O., Santarelli, A., Santharaj, W. S., Sarango, B., Satheesh, S., Schmitz, T., Schuhlen, H., Seewoosagur, R., Segev, A., Seisembekov, V., Semitko, S., Sengottuvelu, G., Sepulveda Varela, P., Sethi, A., Sharma, A., Sharma, R. K., Shi, Hy., Simsek, M. A., Siqueira, B., Skalidis, E., Slawin, J., Sorokhtey, L., Spaulding, C., Srinivas, B., Srinivasan, M., Stakos, D., Stojkovic, S., Tacoy, G., Tawade, M., Tiecco, F., Tondi, S., Torresani, E. M., Tousek, P., Tran, T., Trantalis, G., Triantafyllou, K., Trivedi, R., Trivisonno, A., Tsui, K. L., Turkoglu, C., Tzung-Dau, W., Ueno, H., Urban, U., Uretsky, B. F., Uscumlic, A., Venugopal, V., Verney, R., Vilar, J. V., Villacorta, V. G., Vishwanath, R., Vlachojannis, G. J., Vlachojannis, M., Vlad, V., Von Birgelen, C., Vukcevic, V., Wahab, A., Waksman, R., Wei-Wen, L., Weisz, G., Whittaker, A., Yadav, A., Yokoi, Y., Zacharoulis, A., Zahran, M., Zamani, J., Ziakas, A., Zimmermann, J. P., and Cardiology
- Subjects
Hirudin ,Percutaneous ,Antithrombin ,medicine.medical_treatment ,Psychological intervention ,030204 cardiovascular system & hematology ,medical ,0302 clinical medicine ,Peptide Fragment ,Surveys and Questionnaires ,Surveys and Questionnaire ,Medicine ,Bivalirudin ,030212 general & internal medicine ,Societies, Medical ,Transradial ,Anticoagulant ,Hirudins ,Middle Aged ,Recombinant Protein ,Recombinant Proteins ,Femoral Artery ,Radial Artery ,Cardiology ,acute coronary syndrome ,bivalirudin ,transradial ,adult ,antithrombins ,cardiology ,femoral artery ,hirudins ,humans ,middle aged ,peptide fragments ,percutaneous coronary intervention ,recombinant proteins ,societies, medical ,surveys and questionnaires ,attitude of health personnel ,radial artery ,Acute coronary syndrome ,Cardiology and Cardiovascular Medicine ,Human ,medicine.drug ,Adult ,medicine.medical_specialty ,Attitude of Health Personnel ,medicine.drug_class ,MEDLINE ,Antithrombins ,03 medical and health sciences ,societies ,Percutaneous Coronary Intervention ,Internal medicine ,Humans ,Acute Coronary Syndrome ,Peptide Fragments ,Management of acute coronary syndrome ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,business - Abstract
AIMS Our aim was to report on a survey initiated by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) collecting the opinion of the cardiology community on the invasive management of acute coronary syndrome (ACS), before and after the MATRIX trial presentation at the American College of Cardiology (ACC) 2015 Scientific Sessions. METHODS AND RESULTS A web-based survey was distributed to all individuals registered on the EuroIntervention mailing list (n=15,200). A total of 572 and 763 physicians responded to the pre- and post-ACC survey, respectively. The radial approach emerged as the preferable access site for ACS patients undergoing invasive management with roughly every other responder interpreting the evidence for mortality benefit as definitive and calling for a guidelines upgrade to class I. The most frequently preferred anticoagulant in ACS patients remains unfractionated heparin (UFH), due to higher costs and greater perceived thrombotic risks associated with bivalirudin. However, more than a quarter of participants declared the use of bivalirudin would increase after MATRIX. CONCLUSIONS The MATRIX trial reinforced the evidence for a causal association between bleeding and mortality and triggered consensus on the superiority of the radial versus femoral approach. The belief that bivalirudin mitigates bleeding risk is common, but UFH still remains the preferred anticoagulant based on lower costs and thrombotic risks.
- Published
- 2016
- Full Text
- View/download PDF
14. Outcomes associated with respiratory failure for patients with cardiogenic shock and acute myocardial infarction: a substudy of the culprit-shock trial
- Author
-
Rubini Gimenez, M, primary, Millet, E, additional, Alviar, C, additional, Van Diepen, S, additional, Granger, C, additional, Windecker, S, additional, Serpytis, P, additional, Oldroyd, K, additional, Fuernau, G, additional, Huber, K, additional, Sandri, M, additional, De Waha-Thiele, S, additional, Zeymer, U, additional, Desch, S, additional, and Thiele, H, additional
- Published
- 2020
- Full Text
- View/download PDF
15. Secondhand smoke exposure and survival following acute coronary syndrome: prospective cohort study of 1261 consecutive admissions among never-smokers
- Author
-
Pell, J P, Haw, S, Cobbe, S, Newby, D E, Pell, A C H, Fischbacher, C, Pringle, S, Murdoch, D, Dunn, F, Oldroyd, K, MacIntyre, P, O’Rourke, B, and Borland, W
- Published
- 2009
- Full Text
- View/download PDF
16. Magnetic resonance myocardial perfusion imaging: a new era in the detection of reversible myocardial ischaemia
- Author
-
Watkins, S, Oldroyd, K G, and Frohwein, S
- Published
- 2007
17. Hospital volume of throughput and periprocedural and medium-term adverse events after percutaneous coronary intervention: retrospective cohort study of all 17 417 procedures undertaken in Scotland, 1997–2003
- Author
-
Burton, K R, Slack, R, Oldroyd, K G, Pell, A C H, Flapan, A D, Starkey, I R, Eteiba, H, Jennings, K P, Northcote, R J, Hillis, W Stewart, and Pell, J P
- Published
- 2006
18. Prognostic value and incremental benefit of ischaemic myocardial burden subtended by non-invasive CT-derived fractional flow reserve (FFRCT) significant stenoses.
- Author
-
Khav N., Gaur S., Leipsic J., Osawa K., Miyoshi T., Jensen J., Kimura T., Shiomi H., Erglis A., Oldroyd K., Achenbach S., Nerlekar N., Ko B., Ihdayhid A.R., Norgaard B.L., Khav N., Gaur S., Leipsic J., Osawa K., Miyoshi T., Jensen J., Kimura T., Shiomi H., Erglis A., Oldroyd K., Achenbach S., Nerlekar N., Ko B., Ihdayhid A.R., and Norgaard B.L.
- Abstract
Background: Fractional flow reserve derived from CT-coronary angiography (FFRCT) accurately identifies ischaemic vessels which may be associated with clinical outcomes. Its predictive value in grey zone FFRCT values between 0.7-0.8 is not defined. The technique permits estimation of burden of ischaemic myocardium subtended by FFRCT significant vessels. Purpose(s): To evaluate the prognostic value and incremental benefit of FFRCT defined ischaemic myocardial burden when compared to FFRCT alone. Method(s): This is a subanalysis of NXT (Analysis of Coronary Blood-Flow Using CTA:Next-Steps), a prospective study of stable coronary artery disease (CAD) patients referred for invasive angiography (ICA) undergoing invasive FFR, CTA and FFRCT in whom treating physicians had been blinded to FFRCT results. Primary endpoint, defined as a composite of non-fatal myocardial infarction and any revascularisation, was determined in 206 patients (age 64+/-9.5 years, 64% male) and 618 vessels. Burden of ischaemic myocardium was defined as percentage of myocardium subtended beyond the point at which a vessel's FFRCT becomes <=0.8 as estimated by APPROACH score (FFRCT-APPROACH). In significant FFRCT vessels, the predictive value and incremental benefit of FFRCT-APPROACH was compared with significant FFRCT (<=0.8) for primary endpoint as measured by area under the receiver operator characteristic curve (AUC). Significant ischaemic myocardial burden was defined as >10%. The incidence and relationship between the primary endpoint with each 10% increase in FFRCT-APPROACH and 0.05-unit decrease in FFRCT values <=0.8 was determined. Result(s): Significant FFRCT was identified in 52.9% of patients (109/206) and 29.3% of vessels (181/618). At 4.7 years median follow-up the incidence of the primary endpoint in vessels with significant FFRCTAPPROACH was 58.9% (96/163) which was comparable with vessels with significant FFRCT (55.2%,100/181; P=0.50). The predictive value of FFRCT-APPROACH for the pri
- Published
- 2019
19. Scientific Business Abstracts of the 113th Annual Meeting of the Association of Physicians of Great Britain and Ireland
- Author
-
Cacciottolo, TM, Perikari, A, van der Klaauw, A, Henning, E, Stadler, LKJ, Keogh, J, Farooqi, IS, Tenin, G, Keavney, B, Ryan, E, Budd, R, Bewley, M, Coelho, P, Rumsey, W, Sanchez, Y, McCafferty, J, Dockrell, D, Walmsley, S, Whyte, M, Liu, Y, Choy, M-K, Abraham, S, Black, G, Ford, T, Stanley, B, Good, R, Rocchiccioli, P, McEntegart, M, Watkins, S, Eteiba, H, Shaukat, A, Lindsay, M, Robertson, K, Hood, S, McGeoch, R, McDade, R, Sidik, N, McCartney, P, Corcoran, D, Collison, D, Rush, C, McConnachie, A, Touyz, R, Oldroyd, K, Berry, Colin, Gazdagh, G, Diver, L, Marshall, J, McGowan, R, Ahmed, F, Tobias, E, Curtis, E, Parsons, C, Maslin, K, D’Angelo, S, Moon, R, Crozier, S, Gossiel, F, Bishop, N, Kennedy, S, Papageorghiou, A, Fraser, R, Gandhi, S, Prentice, A, Inskip, H, Godfrey, K, Schoenmakers, I, Javaid, MK, Eastell, R, Cooper, C, Harvey, N, Watt, ER, Howden, A, Mirchandani, A, Hukelmann, JL, Sadiku, P, Plant, TM, Cantrell, DA, Whyte, MKB, Walmsley, SR, Mordi, I, Forteath, C, Wong, A, Mohan, M, Palmer, C, Doney, A, Rena, G, Lang, C, Gray, EH, Azarian, S, Riva, A, Edwards, H, McPhail, MJW, Williams, R, Chokshi, S, Patel, VC, Edwards, LA, Page, D, Miossec, M, Williams, S, Monaghan, R, Fotiou, E, Santibanez-Koref, M, Badat, M, Mettananda, S, Hua, P, Schwessinger, R, Hughes, J, Higgs, D, Davies, J, Cacciottolo, TM, Perikari, A, van der Klaauw, A, Henning, E, Stadler, LKJ, Keogh, J, Farooqi, IS, Tenin, G, Keavney, B, Ryan, E, Budd, R, Bewley, M, Coelho, P, Rumsey, W, Sanchez, Y, McCafferty, J, Dockrell, D, Walmsley, S, Whyte, M, Liu, Y, Choy, M-K, Abraham, S, Black, G, Ford, T, Stanley, B, Good, R, Rocchiccioli, P, McEntegart, M, Watkins, S, Eteiba, H, Shaukat, A, Lindsay, M, Robertson, K, Hood, S, McGeoch, R, McDade, R, Sidik, N, McCartney, P, Corcoran, D, Collison, D, Rush, C, McConnachie, A, Touyz, R, Oldroyd, K, Berry, Colin, Gazdagh, G, Diver, L, Marshall, J, McGowan, R, Ahmed, F, Tobias, E, Curtis, E, Parsons, C, Maslin, K, D’Angelo, S, Moon, R, Crozier, S, Gossiel, F, Bishop, N, Kennedy, S, Papageorghiou, A, Fraser, R, Gandhi, S, Prentice, A, Inskip, H, Godfrey, K, Schoenmakers, I, Javaid, MK, Eastell, R, Cooper, C, Harvey, N, Watt, ER, Howden, A, Mirchandani, A, Hukelmann, JL, Sadiku, P, Plant, TM, Cantrell, DA, Whyte, MKB, Walmsley, SR, Mordi, I, Forteath, C, Wong, A, Mohan, M, Palmer, C, Doney, A, Rena, G, Lang, C, Gray, EH, Azarian, S, Riva, A, Edwards, H, McPhail, MJW, Williams, R, Chokshi, S, Patel, VC, Edwards, LA, Page, D, Miossec, M, Williams, S, Monaghan, R, Fotiou, E, Santibanez-Koref, M, Badat, M, Mettananda, S, Hua, P, Schwessinger, R, Hughes, J, Higgs, D, and Davies, J
- Published
- 2019
20. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial
- Author
-
Thuijs, D. J. F. M., Kappetein, A. P., Serruys, P. W., Mohr, F. -W., Morice, M. -C., Mack, M. J., Holmes, D. R., Curzen, N., Davierwala, P., Noack, T., Milojevic, M., Dawkins, K. D., da Costa, B. R., Juni, P., Head, S. J., Casselman, F., de Bruyne, B., Hoj Christiansen, E., Ruiz-Nodar, J. M., Vermeersch, P., Schultz, W., Sabatelli, Mario, Guagliumi, G., Grubitzsch, H., Stangl, K., Darremont, O., Bentala, M., den Heijer, P., Preda, I., Stoler, R., Szerafin, T., Buckner, J. K., Guber, M. S., Verberkmoes, N., Akca, F., Feldman, T., Beyersdorf, F., Drieghe, B., Oldroyd, K., Berger, Gerit, Jeppsson, A., Barber, K., Wolschleger, K., Heiser, J., van der Harst, P., Mariani, M. A., Reichenspurner, H., Stark, C., Laineri Milazzo, Marco, Ho, P. C., Chen, J. C., Zelman, R., Horwitz, P. A., Bochenek, A., Krauze, A., Grothusen, C., Dudek, D., Heyrich, G., Kolh, P., Legrand, V., Coelho, P., Ensminger, S., Nasseri, B., Ingemansson, R., Olivecrona, G., Escaned, J., Guera, R., Berti, S., Chieffo, A., Burke, N., Mooney, M., Spolaor, A., Hagl, C., Nabauer, M., Suttorp, M. J., Stine, R. A., Mcgarry, T., Lucas, S., Endresen, K., Taussig, A., Accola, K., Canosi, U., Horvath, I., Cannon, L., Talbott, J. D., Akins, C. W., Kramer, R., Aschermann, M., Killinger, W., Narbute, I., Burzotta, Francesco, Bogers, A., Zijlstra, F., Eltchaninoff, H., Berland, J., Stefanini, G., Cruz Gonzalez, I., Hoppe, U., Kiesz, S., Gora, B., Ahlsson, A., Corbascio, M., Bilfinger, T., Carrie, D., Tchetche, D., Hauptman, K. -E., Stahle, E., James, S., Sandner, S., Laufer, G., Lang, I., Witkowski, A., Thourani, V., Suryapranata, H., Redwood, S., Knight, C., Maccarthy, P., de Belder, A., Banning, A., Gershlick, A., Sabate M. (ORCID:0000-0001-6635-4985), Berg G., Laine M., Burzotta F. (ORCID:0000-0002-6569-9401), Thuijs, D. J. F. M., Kappetein, A. P., Serruys, P. W., Mohr, F. -W., Morice, M. -C., Mack, M. J., Holmes, D. R., Curzen, N., Davierwala, P., Noack, T., Milojevic, M., Dawkins, K. D., da Costa, B. R., Juni, P., Head, S. J., Casselman, F., de Bruyne, B., Hoj Christiansen, E., Ruiz-Nodar, J. M., Vermeersch, P., Schultz, W., Sabatelli, Mario, Guagliumi, G., Grubitzsch, H., Stangl, K., Darremont, O., Bentala, M., den Heijer, P., Preda, I., Stoler, R., Szerafin, T., Buckner, J. K., Guber, M. S., Verberkmoes, N., Akca, F., Feldman, T., Beyersdorf, F., Drieghe, B., Oldroyd, K., Berger, Gerit, Jeppsson, A., Barber, K., Wolschleger, K., Heiser, J., van der Harst, P., Mariani, M. A., Reichenspurner, H., Stark, C., Laineri Milazzo, Marco, Ho, P. C., Chen, J. C., Zelman, R., Horwitz, P. A., Bochenek, A., Krauze, A., Grothusen, C., Dudek, D., Heyrich, G., Kolh, P., Legrand, V., Coelho, P., Ensminger, S., Nasseri, B., Ingemansson, R., Olivecrona, G., Escaned, J., Guera, R., Berti, S., Chieffo, A., Burke, N., Mooney, M., Spolaor, A., Hagl, C., Nabauer, M., Suttorp, M. J., Stine, R. A., Mcgarry, T., Lucas, S., Endresen, K., Taussig, A., Accola, K., Canosi, U., Horvath, I., Cannon, L., Talbott, J. D., Akins, C. W., Kramer, R., Aschermann, M., Killinger, W., Narbute, I., Burzotta, Francesco, Bogers, A., Zijlstra, F., Eltchaninoff, H., Berland, J., Stefanini, G., Cruz Gonzalez, I., Hoppe, U., Kiesz, S., Gora, B., Ahlsson, A., Corbascio, M., Bilfinger, T., Carrie, D., Tchetche, D., Hauptman, K. -E., Stahle, E., James, S., Sandner, S., Laufer, G., Lang, I., Witkowski, A., Thourani, V., Suryapranata, H., Redwood, S., Knight, C., Maccarthy, P., de Belder, A., Banning, A., Gershlick, A., Sabate M. (ORCID:0000-0001-6635-4985), Berg G., Laine M., and Burzotta F. (ORCID:0000-0002-6569-9401)
- Abstract
Background: The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial was a non-inferiority trial that compared percutaneous coronary intervention (PCI) using first-generation paclitaxel-eluting stents with coronary artery bypass grafting (CABG) in patients with de-novo three-vessel and left main coronary artery disease, and reported results up to 5 years. We now report 10-year all-cause death results. Methods: The SYNTAX Extended Survival (SYNTAXES) study is an investigator-driven extension of follow-up of a multicentre, randomised controlled trial done in 85 hospitals across 18 North American and European countries. Patients with de-novo three-vessel and left main coronary artery disease were randomly assigned (1:1) to the PCI group or CABG group. Patients with a history of PCI or CABG, acute myocardial infarction, or an indication for concomitant cardiac surgery were excluded. The primary endpoint of the SYNTAXES study was 10-year all-cause death, which was assessed according to the intention-to-treat principle. Prespecified subgroup analyses were performed according to the presence or absence of left main coronary artery disease and diabetes, and according to coronary complexity defined by core laboratory SYNTAX score tertiles. This study is registered with ClinicalTrials.gov, NCT03417050. Findings: From March, 2005, to April, 2007, 1800 patients were randomly assigned to the PCI (n=903) or CABG (n=897) group. Vital status information at 10 years was complete for 841 (93%) patients in the PCI group and 848 (95%) patients in the CABG group. At 10 years, 244 (27%) patients had died after PCI and 211 (24%) after CABG (hazard ratio 1·17 [95% CI 0·97–1·41], p=0·092). Among patients with three-vessel disease, 151 (28%) of 546 had died after PCI versus 113 (21%) of 549 after CABG (hazard ratio 1·41 [95% CI 1·10–1·80]), and among patients with left main coronary artery disease, 93 (26%) of 357 had died after PCI versus 98 (28%) of 348 after CABG (0·90 [0·68–
- Published
- 2019
21. Relation between coronary pressure derived collateral flow, myocardial perfusion grade, and outcome in left ventricular function after rescue percutaneous coronary intervention
- Author
-
Balachandran, K P, Berry, C, Norrie, J, Vallance, B D, Malekianpour, M, Gilbert, T J, Pell, A C H, and Oldroyd, K G
- Published
- 2004
22. Comparison of survival following coronary artery bypass grafting vs. percutaneous coronary intervention in diabetic and non-diabetic patients: retrospective cohort study of 6320 procedures
- Author
-
Pell, J. P., Pell, A. C. H., Jeffrey, R. R., Jennings, K., Oldroyd, K., Eteiba, H., Hogg, K. J., Murday, A., Faichney, A., Colquhoun, I., Berg, G., Starkey, I. R., Flapan, A., and Mankad, P.
- Published
- 2004
23. Resolution of renal artery thrombus with direct administration of tissue plasminogen activator
- Author
-
Balachandran, K P, Pell, A C H, and Oldroyd, K G
- Published
- 2002
24. Rescue percutaneous coronary intervention for failed thrombolysis: results from a district general hospital
- Author
-
Balachandran, K P, Miller, J, Pell, A C H, Vallance, B D, and Oldroyd, K G
- Published
- 2002
25. Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide
- Author
-
Balachandran, K P, Stewart, D, Berg, G A, and Oldroyd, K G
- Published
- 2002
26. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial
- Author
-
Layland, J., Oldroyd, K. G., Curzen, N., Sood, A., Balachandran, K., Das, R., Junejo, S., Ahmed, N., Lee, M.M.Y., Shaukat, A., O'Donnell, A., Nam, J., Briggs, A., Henderson, R., McConnachie, A., Berry, C., Hannah, A., Stewart, A., Metcalfe, M., Norrie, J., Chowdhary, S., Clark, A., Baird, G., Ford, I., and Oldroyd, K.
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,Medical therapy ,medicine.medical_treatment ,Myocardial Infarction ,Fractional flow reserve ,Coronary Angiography ,Radiography, Interventional ,Coronary revascularization ,Revascularization ,Electrocardiography ,Coronary artery bypass surgery ,Internal medicine ,Myocardial Revascularization ,medicine ,Humans ,ST segment ,Prospective Studies ,Myocardial infarction ,FASTTrack Clinical Research ,business.industry ,Coronary Stenosis ,Percutaneous coronary intervention ,Middle Aged ,medicine.disease ,Surgery ,Hospitalization ,Fractional Flow Reserve, Myocardial ,Treatment Outcome ,Conventional PCI ,Costs and Cost Analysis ,Quality of Life ,Cardiology ,Health Resources ,Female ,Non-ST elevation myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Acute Coronary Syndromes - Abstract
Aim We assessed the management and outcomes of non-ST segment elevation myocardial infarction (NSTEMI) patients randomly assigned to fractional flow reserve (FFR)-guided management or angiography-guided standard care. Methods and results We conducted a prospective, multicentre, parallel group, 1 : 1 randomized, controlled trial in 350 NSTEMI patients with ≥1 coronary stenosis ≥30% of the lumen diameter assessed visually (threshold for FFR measurement) ([NCT01764334][1]). Enrolment took place in six UK hospitals from October 2011 to May 2013. Fractional flow reserve was disclosed to the operator in the FFR-guided group ( n = 176). Fractional flow reserve was measured but not disclosed in the angiography-guided group ( n = 174). Fractional flow reserve ≤0.80 was an indication for revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). The median (IQR) time from the index episode of myocardial ischaemia to angiography was 3 (2, 5) days. For the primary outcome, the proportion of patients treated initially by medical therapy was higher in the FFR-guided group than in the angiography-guided group [40 (22.7%) vs. 23 (13.2%), difference 95% (95% CI: 1.4%, 17.7%), P = 0.022]. Fractional flow reserve disclosure resulted in a change in treatment between medical therapy, PCI or CABG in 38 (21.6%) patients. At 12 months, revascularization remained lower in the FFR-guided group [79.0 vs. 86.8%, difference 7.8% (−0.2%, 15.8%), P = 0.054]. There were no statistically significant differences in health outcomes and quality of life between the groups. Conclusion In NSTEMI patients, angiography-guided management was associated with higher rates of coronary revascularization compared with FFR-guided management. A larger trial is necessary to assess health outcomes and cost-effectiveness. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01764334&atom=%2Fehj%2Fearly%2F2014%2F08%2F25%2Feurheartj.ehu338.atom
- Published
- 2014
- Full Text
- View/download PDF
27. Outcomes following coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in the stent era: a prospective study of all 9890 consecutive patients operated on in Scotland over a two year period
- Author
-
Pell, J P, Walsh, D, Norrie, J, Berg, G, Colquhoun, A D, Davidson, K, Eteiba, H, Faichney, A, Flapan, A, Hogg, K J, Jeffrey, R R, Jennings, K, McArthur, J, Mankad, P, Oldroyd, K, Pell, A C H, and Starkey, I R
- Published
- 2001
28. Identifying failure to achieve complete (TIMI 3) reperfusion following thrombolytic treatment: how to do it, when to do it, and why itʼs worth doing
- Author
-
OLDROYD, K G
- Published
- 2000
29. Access site and outcomes for unprotected left main stem PCI: an analysis of the British Cardiovascular Intervention Society database
- Author
-
Kinnaird, T, Anderson, R, Gallagher, S, Sirker, A, Ludman, P, De Belder, M, Copt, S, Oldroyd, K, Curzen, N, Banning, A, and Mamas, M
- Subjects
RC666 - Abstract
Objectives\ud Using the British Cardiovascular Intervention Society percutaneous coronary intervention (PCI) database, temporal trends, predictors, and outcomes of radial access (RA) versus femoral access (FA) for unprotected left main stem percutaneous coronary intervention (LMS-PCI) were studied.\ud \ud Background\ud Data on arterial access site for LMS-PCI are poorly defined.\ud \ud Methods\ud Data were analyzed from 19,482 LMS-PCI procedures performed in England and Wales between 2007 and 2014. Multivariate logistic regression was used to identify predictors of access site choice and its association with outcomes.\ud \ud Results\ud The frequency of FA use fell from 77.7% in 2007 to 31.7% in 2014 (p < 0.001 for trend). In the most contemporary study years (2012 to 2014), the strongest associates of FA use for unprotected LMS-PCI were renal disease, PCI for restenosis, chronic total occlusion intervention, and female sex. Use of intravascular imaging and chronic anticoagulation were associated with a higher likelihood of RA use. Complexity of the PCI procedure in the RA cohort increased significantly during the study period. Length of stay was shorter (2.6 ± 9.2 vs. 3.6 ± 9.0; p < 0.001) and same day discharge greater (43.0% vs. 26.6%; p < 0.001) with RA use. After propensity matching, RA use was associated with significant reductions in in-hospital events including access site arterial complications, major bleeding, and major adverse cardiovascular events. Conversion to RA for LMS-PCI was associated with similar reductions in the whole patient cohort. RA use was not associated with lower 12-month mortality.\ud \ud Conclusions\ud In contemporary practice, the radial artery is the predominant access site for unprotected LMS-PCI, and its use is associated with shorter length of stay, less vascular complications, and less major bleeding than femoral access.
- Published
- 2018
30. Five-year outcomes with PCI guided by fractional flow reserve
- Author
-
Xaplanteris, P., Fournier, S., Pijls, N. H. J., Fearon, W. F., Barbato, E., Tonino, P. A. L., Engstrøm, T., Kääb, S., Dambrink, J. H., Toth, G. G., Rioufol, G., Piroth, Z., Witt, N., Fröbert, O., Kala, P., Linke, A., Jagic, N., Mates, M., Mavromatis, K., Samady, H., Irimpen, A., Oldroyd, K., Campo, G., Rothenbühler, M., Jüni, P., de Bruyne, B., Mulder, Barbara J. M., et al, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Department of Cardiology, Örebro University, Cardiovascular Biomechanics, Cardiology, APH - Personalized Medicine, APH - Aging & Later Life, ACS - Heart failure & arrhythmias, Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), CarMeN, laboratoire, Xaplanteris, Panagioti, Fournier, Stephane, Pijls, Nico H J, Fearon, William F, Barbato, Emanuele, Tonino, Pim A L, Engstrøm, Thoma, Kääb, Stefan, Dambrink, Jan-Henk, Rioufol, Gille, Toth, Gabor G, Piroth, Zsolt, Witt, Nil, Fröbert, Ole, Kala, Petr, Linke, Axel, Jagic, Nicola, Mates, Martin, Mavromatis, Kreton, Samady, Habib, Irimpen, Anand, Oldroyd, Keith, Campo, Gianluca, Rothenbühler, Martina, Jüni, Peter, and De Bruyne, Bernard
- Subjects
st-segment elevation ,Male ,task-force ,Coronary Stenosi ,Platelet Aggregation Inhibitors/therapeutic use ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Myocardial Infarction ,Coronary Disease ,Fractional flow reserve ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Coronary artery disease ,0302 clinical medicine ,Drug-Eluting Stent ,030212 general & internal medicine ,Myocardial infarction ,guidelines ,Medicine (all) ,Angina Pectori ,Hazard ratio ,Drug-Eluting Stents ,General Medicine ,Middle Aged ,Fractional Flow Reserve ,myocardial-infarction ,3. Good health ,[SDV] Life Sciences [q-bio] ,Fractional Flow Reserve, Myocardial ,Antihypertensive Agent ,Coronary Disease/drug therapy ,Aged ,Angina Pectoris ,Antihypertensive Agents ,Coronary Stenosis ,Female ,Follow-Up Studies ,Humans ,Platelet Aggregation Inhibitors ,Retreatment ,Percutaneous Coronary Intervention ,Cardiology ,Platelet aggregation inhibitor ,management ,Human ,medicine.medical_specialty ,Angina Pectoris/therapy ,conservative treatment ,Revascularization ,Follow-Up Studie ,european-society ,NO ,03 medical and health sciences ,Internal medicine ,General & Internal Medicine ,medicine ,Myocardial Infarction/epidemiology ,Myocardial ,coronary ,Antihypertensive Agents/therapeutic use ,business.industry ,Platelet Aggregation Inhibitor ,prospective natural-history ,Percutaneous coronary intervention ,medicine.disease ,medical therapy ,Retreatment/statistics & numerical data ,Conventional PCI ,Coronary Stenosis/drug therapy ,business - Abstract
Background: we hypothesized that fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) would be superior to medical therapy as initial treatment in patients with stable coronary artery disease.Methods: among 1220 patients with angiographically significant stenoses, those in whom at least one stenosis was hemodynamically significant (FFR, ≤0.80) were randomly assigned to FFR-guided PCI plus medical therapy or to medical therapy alone. Patients in whom all stenoses had an FFR of more than 0.80 received medical therapy and were entered into a registry. The primary end point was a composite of death, myocardial infarction, or urgent revascularization.Results: a total of 888 patients underwent randomization (447 patients in the PCI group and 441 in the medical-therapy group). At 5 years, the rate of the primary end point was lower in the PCI group than in the medical-therapy group (13.9% vs. 27.0%; hazard ratio, 0.46; 95% confidence interval [CI], 0.34 to 0.63; PConclusions: in patients with stable coronary artery disease, an initial FFR-guided PCI strategy was associated with a significantly lower rate of the primary composite end point of death, myocardial infarction, or urgent revascularization at 5 years than medical therapy alone. Patients without hemodynamically significant stenoses had a favorable long-term outcome with medical therapy alone. (Funded by St. Jude Medical and others; FAME 2 ClinicalTrials.gov number, NCT01132495 .).
- Published
- 2018
31. Sex Differences in Adenosine-Free Coronary Pressure Indexes A CONTRAST Substudy
- Author
-
Shah, S. V., Zimmermann, F. M., Johnson, N. P., Nishi, T., Kobayashi, Y., Witt, N., Berry, C., Jeremias, A., Koo, B. K., Esposito, G., Rioufol, Gilles, Park, S. J., Oldroyd, K. G., Barbato, E., Pijls, N. H. J., De Bruyne, B., Fearon, W. F., Investigators, Contrast Study, CarMeN, laboratoire, Kyoto University [Kyoto], Macaulay Institute, Università degli studi di Cassino e del Lazio Meridionale (UNICAS), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Chonbuk National University, Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National de la Recherche Agronomique (INRA)
- Subjects
dysfunction ,[SDV]Life Sciences [q-bio] ,differences ,advise ii ,gender-differences ,artery-disease ,[SDV] Life Sciences [q-bio] ,contrast fractional flow reserve ,Cardiovascular System & Cardiology ,clinical-outcomes ,sex ,multivessel evaluation ,microvascular ,stenosis severity ,diagnostic-accuracy ,fractional flow reserve ,wave-free ratio - Abstract
OBJECTIVES The goal of this study was to investigate sex differences in adenosine-free coronary pressure indexes. BACKGROUND Several adenosine-free coronary pressure wire indexes have been proposed to assess the functional significance of coronary artery lesions; however, there is a theoretical concern that sex differences may affect diagnostic performance because of differences in resting flow and distal myocardial mass. METHODS In this CONTRAST (Can Contrast Injection Better Approximate FFR Compared to Pure Resting Physiology?) substudy, contrast fractional flow reserve (cFFR), obtained during contrast-induced submaximal hyperemia, the instantaneous wave-free ratio (iFR), and distal/proximal coronary pressure ratio (Pd/Pa) were compared with fractional flow reserve (FFR) in 547 men and 216 women. Using FFR \textless= 0.8 as a reference, the diagnostic performance of each index was compared. RESULTS Men and women had similar diameter stenosis (p = 0.78), but women were less likely to have FFR \textless= 0.80 than men (42.5% vs. 51.5%, p = 0.04). Sensitivity was similar among cFFR, iFR, and Pd/Pa when comparing women and men, respectively (cFFR, 77.5% vs. 75.3%; p = 0.69; iFR, 84.9% vs. 79.4%; p = 0.30; Pd/Pa, 78.8% vs. 77.3%; p = 0.78). cFFR was more specific than iFR or Pd/Pa regardless of sex (cFFR, 94.3% vs. 95.8%; p = 0.56; iFR, 75.6% vs. 80.1%; p = 0.38; Pd/Pa, 80.6% vs. 78.7%; p = 0.69). By receiver-operating characteristic curve analysis, cFFR provided better diagnostic accuracy than resting indexes irrespective of sex (p \textless= 0.0001). CONCLUSIONS Despite the theoretical concern, the diagnostic sensitivity and specificity of cFFR, iFR, and Pd/Pa did not differ between the sexes. Irrespective of sex, cFFR provides the best diagnostic performance. (C) 2018 by the American College of Cardiology Foundation.
- Published
- 2018
32. 6030Effects of adjunctive treatment with low-dose alteplase during primary percutaneous coronary intervention according to ischaemic time
- Author
-
McCartney, P, primary, Maznyczka, A, additional, Eteiba, H, additional, McEntegart, M, additional, Greenwood, J P, additional, Schmitt, M, additional, Maredia, N, additional, McCann, G P, additional, Fairbairn, T, additional, McAlindon, E, additional, Oldroyd, K G, additional, Orchard, V, additional, Radjenovic, A, additional, McConnachie, A, additional, and Berry, C, additional
- Published
- 2019
- Full Text
- View/download PDF
33. 127Prevalence of coronary artery disease and coronary microvascular dysfunction in heart failure with preserved ejection fraction
- Author
-
Rush, C, primary, Berry, C, additional, Oldroyd, K, additional, Rocchiccioli, P, additional, Lindsay, M, additional, Campbell, R, additional, Ford, T, additional, Sidik, N, additional, Murphy, C, additional, Touyz, R, additional, Petrie, M, additional, and McMurray, J, additional
- Published
- 2019
- Full Text
- View/download PDF
34. P328Is there evidence of a rebound increase in platelet aggregation following withdrawal of Aspirin or Ticagrelor in patients who have previously undergone PCI and coronary stenting?
- Author
-
Hennigan, B W, primary, Good, R, additional, Adamson, C, additional, Martin, L, additional, Anderson, L, additional, Campbell, M, additional, and Oldroyd, K G, additional
- Published
- 2019
- Full Text
- View/download PDF
35. P2238Prognostic value and incremental benefit of ischaemic myocardial burden subtended by non-invasive CT-derived fractional flow reserve (FFRCT) significant stenoses
- Author
-
Ihdayhid, A R, primary, Norgaard, B L, additional, Khav, N, additional, Gaur, S, additional, Leipsic, J, additional, Nerlekar, N, additional, Osawa, K, additional, Miyoshi, T, additional, Jensen, J, additional, Kimura, T, additional, Shiomi, H, additional, Erglis, A, additional, Oldroyd, K, additional, Achenbach, S, additional, and Ko, B, additional
- Published
- 2019
- Full Text
- View/download PDF
36. P2707Invasive coronary physiology during primary percutaneous coronary intervention in patients treated with intracoronary alteplase or placebo: the double-blind T-TIME physiology substudy
- Author
-
Maznyczka, A, primary, McCartney, P, additional, Oldroyd, K G, additional, McEntegart, M, additional, Lindsay, M, additional, Eteiba, H, additional, Rocchiccioli, P, additional, Good, R, additional, Shaukat, A, additional, Kodoth, V, additional, Greenwood, J, additional, Robertson, K, additional, Cotton, J, additional, McConnachie, A, additional, and Berry, C, additional
- Published
- 2019
- Full Text
- View/download PDF
37. Do radionuclide and echocardiographic techniques give a universal cut off value for left ventricular ejection fraction that can be used to select patients for treatment with ACE inhibitors after myocardial infarction?
- Author
-
Ray, S. G., Metcalfe, M. J., Oldroyd, K. G., Pye, M., Martin, W., Christie, J., Dargie, H. J., and Cobbe, S. M.
- Published
- 1995
38. Activation and inhibition of the endogenous opioid system in human heart failure
- Author
-
Oldroyd, K. G., Gray, C. E., Carter, R., Harvey, K., Borland, W., Beastall, G., and Cobbe, S. M.
- Published
- 1995
39. One-Year Outcomes after PCI Strategies in Cardiogenic Shock
- Author
-
Thiele, H., Akin, I., Sandri, M., Waha-Thiele, S. de, Meyer-Saraei, R., Fuernau, G., Eitel, I., Nordbeck, P., Geisler, T., Landmesser, U., Skurk, C., Fach, A., Jobs, A., Lapp, H., Piek, J.J., Noc, M., Goslar, T., Felix, S.B., Maier, L.S., Stepinska, J., Oldroyd, K., Serpytis, P., Montalescot, G., Barthelemy, O., Huber, K., Windecker, S., Hunziker, L., Savonitto, S., Torremante, P., Vrints, C., Schneider, S., Geuns, R.J.M. van, Zeymer, U., Desch, S., Thiele, H., Akin, I., Sandri, M., Waha-Thiele, S. de, Meyer-Saraei, R., Fuernau, G., Eitel, I., Nordbeck, P., Geisler, T., Landmesser, U., Skurk, C., Fach, A., Jobs, A., Lapp, H., Piek, J.J., Noc, M., Goslar, T., Felix, S.B., Maier, L.S., Stepinska, J., Oldroyd, K., Serpytis, P., Montalescot, G., Barthelemy, O., Huber, K., Windecker, S., Hunziker, L., Savonitto, S., Torremante, P., Vrints, C., Schneider, S., Geuns, R.J.M. van, Zeymer, U., and Desch, S.
- Abstract
Item does not contain fulltext, BACKGROUND: Among patients with acute myocardial infarction, cardiogenic shock, and multivessel coronary artery disease, the risk of a composite of death from any cause or severe renal failure leading to renal-replacement therapy at 30 days was found to be lower with percutaneous coronary intervention (PCI) of the culprit lesion only than with immediate multivessel PCI. We evaluated clinical outcomes at 1 year. METHODS: We randomly assigned 706 patients to either culprit-lesion-only PCI or immediate multivessel PCI. The results for the primary end point of death or renal-replacement therapy at 30 days have been reported previously. Prespecified secondary end points at 1 year included death from any cause, recurrent myocardial infarction, repeat revascularization, rehospitalization for congestive heart failure, the composite of death or recurrent infarction, and the composite of death, recurrent infarction, or rehospitalization for heart failure. RESULTS: As reported previously, at 30 days, the primary end point had occurred in 45.9% of the patients in the culprit-lesion-only PCI group and in 55.4% in the multivessel PCI group (P=0.01). At 1 year, death had occurred in 172 of 344 patients (50.0%) in the culprit-lesion-only PCI group and in 194 of 341 patients (56.9%) in the multivessel PCI group (relative risk, 0.88; 95% confidence interval [CI], 0.76 to 1.01). The rate of recurrent infarction was 1.7% with culprit-lesion-only PCI and 2.1% with multivessel PCI (relative risk, 0.85; 95% CI, 0.29 to 2.50), and the rate of a composite of death or recurrent infarction was 50.9% and 58.4%, respectively (relative risk, 0.87; 95% CI, 0.76 to 1.00). Repeat revascularization occurred more frequently with culprit-lesion-only PCI than with multivessel PCI (in 32.3% of the patients vs. 9.4%; relative risk, 3.44; 95% CI, 2.39 to 4.95), as did rehospitalization for heart failure (5.2% vs. 1.2%; relative risk, 4.46; 95% CI, 1.53 to 13.04). CONCLUSIONS: Among patients with acute myo
- Published
- 2018
40. Serum interleukin-6 in suspected myocardial infarction
- Author
-
Cruickshank, Anne M, Oldroyd, K G, and Cobbe, S M
- Published
- 1994
41. 3283Long-term prognostic value of non-invasive fractional flow reserve derived from coronary CT angiography (FFRct)
- Author
-
Ihdayhid, A R, primary, Norgaard, B L, additional, Gaur, S, additional, Leipsic, J, additional, Osawa, K, additional, Miyoshi, T, additional, Jensen, J, additional, Kimura, T, additional, Shiomi, H, additional, Erglis, A, additional, Jegere, S, additional, Oldroyd, K G, additional, Seneviratne, S, additional, Achenbach, S, additional, and Ko, B S, additional
- Published
- 2018
- Full Text
- View/download PDF
42. Cardiac Catheterisation By The Judkins Technique As An Outpatient Procedure
- Author
-
Oldroyd, K. G., Phadke, K. V., Phillips, R., Carson, P. H. M., Clarke, M., and Davis, J. A. S.
- Published
- 1989
43. Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial
- Author
-
Lemmert, M.E., Oldroyd, K., Barragan, P., Lesiak, M., Byrne, R.A., Merkulov, E., Daemen, J., Onuma, Y., Witberg, K., Geuns, R.J.M. van, Lemmert, M.E., Oldroyd, K., Barragan, P., Lesiak, M., Byrne, R.A., Merkulov, E., Daemen, J., Onuma, Y., Witberg, K., and Geuns, R.J.M. van
- Abstract
Contains fulltext : 182905.pdf (Publisher’s version ) (Open Access), BACKGROUND: Continuous improvements in stent technology make percutaneous coronary intervention (PCI) a potential alternative to surgery in selected patients with unprotected left main coronary artery (uLMCA) disease. The optimal duration of dual antiplatelet therapy (DAPT) in these patients remains undetermined, and in addition, new stent designs using a bioabsorbable polymer might allow shorter duration of DAPT. STUDY DESIGN: IDEAL-LM is a prospective, randomized, multicenter study that will enroll 818 patients undergoing uLMCA PCI. Patients will be randomized in a 1:1 fashion to intravascular ultrasound-guided PCI with the novel everolimus-eluting platinum-chromium Synergy stent with a biodegradable polymer (Boston Scientific, Natick, MA) followed by 4 months of DAPT or the everolimus-eluting cobalt-chromium Xience stent (Abbott Vascular, Santa Clara, CA) followed by 12 months of DAPT. The total follow-up period will be 5 years. A subset of 100 patients will undergo optical coherence tomography at 3 months. END POINTS: The primary end point will be major adverse cardiovascular events (composite of all-cause mortality, myocardial infarction, and ischemia-driven target vessel revascularization) at 2 years. Secondary end points will consist of the individual components of the primary end point, procedural success, a device-oriented composite end point, stent thrombosis as per Academic Research Consortium criteria, and bleeding as per Bleeding Academic Research Consortium criteria. SUMMARY: IDEAL-LM is designed to assess the safety and efficacy of the novel Synergy stent followed by 4 months of DAPT vs the Xience stent followed by 12 months of DAPT in patients undergoing uLMCA PCI. The study will provide novel insights regarding optimal treatment strategy for patients undergoing PCI of uLMCA disease (www.clinicaltrials.gov, NCT 02303717).
- Published
- 2017
44. Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial
- Author
-
Lemmert, Miguel, Oldroyd, K, Barragan, P, Lesiak, M, Byrne, RA, Merkulov, E, Daemen, Joost, Onuma, Yoshinobu, Witberg, Karen, van Geuns, Robert Jan, Lemmert, Miguel, Oldroyd, K, Barragan, P, Lesiak, M, Byrne, RA, Merkulov, E, Daemen, Joost, Onuma, Yoshinobu, Witberg, Karen, and van Geuns, Robert Jan
- Published
- 2017
45. Fractional flow reserve-guided PCI for stable coronary artery disease
- Author
-
De Bruyne B, Fearon WF, Pijls NH, Tonino P, Piroth Z, Jagic N, Mobius Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstr?m T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, N?esch E, J?ni P, FAME 2 Trial Investigators, BARBATO, EMANUELE, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), De Bruyne, B, Fearon, Wf, Pijls, Nh, Barbato, Emanuele, Tonino, P, Piroth, Z, Jagic, N, Mobius Winckler, S, Rioufol, G, Witt, N, Kala, P, Maccarthy, P, Engstr?m, T, Oldroyd, K, Mavromatis, K, Manoharan, G, Verlee, P, Frobert, O, Curzen, N, Johnson, Jb, Limacher, A, N?esch, E, J?ni, P, Fame, 2 Trial Investigators, and Cardiovascular Biomechanics
- Subjects
Coronary Disease/drug therapy/mortality/physiopathology/*therapy ,medicine.medical_specialty ,medicine.medical_treatment ,Fractional Flow Reserve ,[SDV]Life Sciences [q-bio] ,610 Medicine & health ,Fractional flow reserve ,Kaplan-Meier Estimate ,Revascularization ,Coronary artery disease ,360 Social problems & social services ,Internal medicine ,medicine ,Myocardial Infarction/epidemiology/prevention & control ,Humans ,Myocardial ,Myocardial infarction ,Instantaneous wave-free ratio ,Proportional Hazards Models ,business.industry ,Hazard ratio ,Percutaneous coronary intervention ,General Medicine ,medicine.disease ,Adrenergic beta-Antagonists/therapeutic use ,Combined Modality Therapy ,Angiotensin Receptor Antagonists/therapeutic use ,3. Good health ,Surgery ,Angiotensin-Converting Enzyme Inhibitors/therapeutic use ,Conventional PCI ,Cardiology ,Percutaneous Coronary Intervention/adverse effects/*methods ,business - Abstract
International audience; BACKGROUND: We hypothesized that in patients with stable coronary artery disease and stenosis, percutaneous coronary intervention (PCI) performed on the basis of the fractional flow reserve (FFR) would be superior to medical therapy. METHODS: In 1220 patients with stable coronary artery disease, we assessed the FFR in all stenoses that were visible on angiography. Patients who had at least one stenosis with an FFR of 0.80 or less were randomly assigned to undergo FFR-guided PCI plus medical therapy or to receive medical therapy alone. Patients in whom all stenoses had an FFR of more than 0.80 received medical therapy alone and were included in a registry. The primary end point was a composite of death from any cause, nonfatal myocardial infarction, or urgent revascularization within 2 years. RESULTS: The rate of the primary end point was significantly lower in the PCI group than in the medical-therapy group (8.1% vs. 19.5%; hazard ratio, 0.39; 95% confidence interval [CI], 0.26 to 0.57; P\textless0.001). This reduction was driven by a lower rate of urgent revascularization in the PCI group (4.0% vs. 16.3%; hazard ratio, 0.23; 95% CI, 0.14 to 0.38; P\textless0.001), with no significant between-group differences in the rates of death and myocardial infarction. Urgent revascularizations that were triggered by myocardial infarction or ischemic changes on electrocardiography were less frequent in the PCI group (3.4% vs. 7.0%, P=0.01). In a landmark analysis, the rate of death or myocardial infarction from 8 days to 2 years was lower in the PCI group than in the medical-therapy group (4.6% vs. 8.0%, P=0.04). Among registry patients, the rate of the primary end point was 9.0% at 2 years. CONCLUSIONS: In patients with stable coronary artery disease, FFR-guided PCI, as compared with medical therapy alone, improved the outcome. Patients without ischemia had a favorable outcome with medical therapy alone. (Funded by St. Jude Medical; FAME 2 ClinicalTrials.gov number, NCT01132495.).
- Published
- 2014
- Full Text
- View/download PDF
46. Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated everolimus-eluting stent.
- Author
-
Dawkins K.D., Carrie D., Walsh S., Oldroyd K., Varenne O., El-Jack S., Moreno R., Allocco D.J., Meredith I.T., Verheye S., Dubois C., Dens J., Farah B., Dawkins K.D., Carrie D., Walsh S., Oldroyd K., Varenne O., El-Jack S., Moreno R., Allocco D.J., Meredith I.T., Verheye S., Dubois C., Dens J., and Farah B.
- Abstract
Aims: The SYNERGY stent has a unique design to enhance optimal intravascular healing. The EVOLVE study compared the performance of the bioabsorbable polymer SYNERGY everolimus-eluting stent (EES at 2 doses) to the permanent polymer PROMUS Element EES. Methods and Results: The EVOLVE trial was a prospective,multicentre, randomised, controlled first human use trial enrolling patients with a de novo lesion <=28 mm in length in a coronary artery >=2.25 and <=3.5 mm in diameter. Patients were randomised 1:1:1 to treatment with one of three stents: PROMUS Element (N=98), SYNERGY stents releasing everolimus at an equivalent dose to PROMUS Element ("SYNERGY" group; N=94) and SYNERGY stents releasing half-dose everolimus ("SYNERGY 1/2 Dose" group; N=99). The primary clinical endpoint was 30-day target lesion failure (defined as target vessel-related cardiac death, target vessel-related myocardial infarction (MI), or target lesion revascularisation). At 30 days, the rate of TLF was not significantly different among groups; 0% in the PROMUS Element arm, 1.1% with SYNERGY, and 3.1% in the SYNERGY 1/2 Dose group (PROMUS Element: vs SYNERGYP=0.49; vs SYNERGY 1/2 Dose P=0.25). The primary angiographic endpoint of 6-month in-stent late loss was non-inferior between the control and SYNERGY groups (0.15+/-0.34 mm for PROMUS Element, 0.10+/-0.25 mm for SYNERGY, and 0.13+/-0.26 mm for SYNERGY 1/2 Dose; PROMUS Element: vs SYNERGY P=0.19; vs SYNERGY 1/2 Dose P=0.56). Four-year clinical event rates including TLF, TVF, death, MI and revascularisation were low and not significantly different between groups. At 4 years, the rate of TLF was 8.4% in the PROMUS Element group, 5.5% in the SYNERGY group and 5.2% in the SYNERGY 1/2 Dose group (PROMUS Element: vs SYNERGY P=0.64; vs SYNERGY 1/2 Dose, P=0.59). No TLF events were reported between 2 to 4 years of follow-up in either SYNERGY cohort. TVF at 4 years was 12.4% in the PROMUS Element group, 7.7% in the SYNERGY group and 8.3% in the SYNERGY 1
- Published
- 2016
47. One Year Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention Using the Hybrid Approach
- Author
-
Wilson, W., primary, Walsh, S., additional, Hanratty, C., additional, Bagnall, A., additional, Yan, A., additional, Egred, M., additional, Smith, E., additional, Oldroyd, K., additional, McEntegart, M., additional, Irving, J., additional, Strange, J., additional, and Spratt, J., additional
- Published
- 2016
- Full Text
- View/download PDF
48. Hybrid approach improves success of chronic total occlusion angioplasty
- Author
-
Wilson, W M, primary, Walsh, S J, additional, Yan, A T, additional, Hanratty, C G, additional, Bagnall, A J, additional, Egred, M, additional, Smith, E, additional, Oldroyd, K G, additional, McEntegart, M, additional, Irving, J, additional, Strange, J, additional, Douglas, H, additional, and Spratt, J C, additional
- Published
- 2016
- Full Text
- View/download PDF
49. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
- Author
-
Tricoci, P, Huang, Z, Held, C, Moliterno, Dj, Armstrong, Pw, Van de Werf, F, White, Hd, Aylward, Pe, Wallentin, L, Chen, E, Lokhnygina, Y, Pei, J, Leonardi, S, Rorick, Tl, Kilian, Am, Jennings, Lh, Ambrosio, G, Bode, C, Cequier, A, Cornel, Jh, Diaz, R, Erkan, A, Huber, K, Hudson, Mp, Jiang, L, Jukema, Jw, Lewis, Bs, Lincoff, Am, Montalescot, G, Nicolau, Jc, Ogawa, H, Pfisterer, M, Prieto, Jc, Ruzyllo, W, Sinnaeve, Pr, Storey, Rf, Valgimigli, M, Whellan, Dj, Widimsky, P, Strony, J, Harrington, Ra, Mahaffey, Kw, Huo, Y, Lixin, J, Isaza, D, Grande, P, Laine, M, Wong, L, Ofner, P, Yamaguchi, T, Park, Sj, Nordrehaug, Je, Providencia, L, Cheem, Th, Dalby, A, Betriu, A, Chen, Mf, Verheugt, F, Frye, Rl, Hochman, J, Steg, Pg, Bailey, Kr, Easton, Jd, Lincoff, A, Underwood, Fd, Wrestler, J, Larson, D, Vandyne, B, Kilian, A, Harmelin-Kadouri, R, Layton, L, Lipka, L, Petrauskas, S, Qidwai, M, Sorochuck, C, Temple, T, Mason, D, Sydlowski, D, Gallagher, B, Villasin, A, Beernaert, A, Douglas, S, Garrett, J, Wiering, J, Adriaenssens, T, Ganame, J, Hulselmans, M, Katz, Jn, Kayaert, P, La Gerche, A, Onsea, K, Zalewski, J, Johnson, A, O'Briant, J, Smith, M, Akerblom, A, Armaganijan, L, Bertolami, A, Brennan, M, da Ponte Nacif SA, de Campos Gonzaga, C, Dequadros, A, Déry, Jp, Dev, S, Ducrocq, G, Eapen, Zp, Echenique, L, Eggers, K, Garcia, H, Guimaraes, Hp, Hagstrom, E, Hanet, C, James, S, Jonelid, B, Kolls, Bj, Leiria, T, Leite, R, Lombardi, C, Lopes, Rd, Malagutti, P, Mathews, R, Mehta, Rh, Melloni, C, Piccini, Jp, Rodriques Soares, P, Roe, Mt, Shah, Br, Stashenko, G, Szczech, La, Truffa, A, Varenhorst, C, Vranckx, P, Williams, J, Kilaru, R, White, Ja, Binkowitz, B, He, W, Ramos, Ms, Hasbani, E, Farras, Ha, Luz del Valle, L, Zapata, G, Centeno, Ep, Hominal, M, Beloscar, J, Panno, M, Berli, M, Carlevaro, O, Wasserman, T, Lembo, L, Diez, F, Bettinotti, M, Allall, O, Macin, S, Hii, C, Bett, N, Aroney, C, Roberts-Thomson, P, Arstall, M, Horowitz, J, Prasan, A, Farshid, A, Rankin, J, Duffy, S, Sinhal, A, Hendricks, R, Waites, J, Hill, A, French, J, Adams, M, Soward, A, Dick, R, Jepson, N, Nelson, G, Thompson, P, Neunteufl, T, Pachinger, O, Leisch, F, Siostrzonek, P, Roithinger, F, Pieske, B, Weber, H, Eber, B, Zenker, G, Sinnaeve, P, Roosen, J, Vervoort, G, Coussement, P, Striekwold, H, Boland, J, Van Dorpe, A, Dujardin, K, Mertens, D, Vanneste, L, Celen, H, Lesseliers, H, Vrolix, M, Leone, A, De Maeseneire, S, Hellemans, S, Silva, Fa, Franken, M, Moraes JB Jr, Mora, R, Michalaros, Y, Perin, M, Guimaraes, Ae, da Silva DG, Mattos, Ma, Alves AR Jr, Hernandes, Me, Golin, V, da Silva SA, Ardito, W, Dery, Jp, Mukherjee, A, Tanguay, Jf, Kornder, J, Lutchmedial, S, Degrace, M, Klinke, P, Constance, C, Nogareda, G, Wong, G, Macdonald, P, Senaratne, M, Rupka, D, Halperin, F, Ramanathan, K, Natarajan, M, Lai, C, Brossoit, R, Tymchak, W, Rose, B, Dupuis, R, Mansour, S, Bata, I, Zadra, R, Turek, M, Madan, M, Le May, M, Leon, L, Perez, L, Yovaniniz, P, Pedemonte, O, Campos, P, Pincetti, C, Sepulveda, P, Li, W, Zhao, R, Li, Z, Yang, Y, Chen, J, Li, H, Jiang, Y, Li, D, Qu, P, Sun, Y, Zheng, Y, Zhou, C, Zhang, F, Wei, M, Wang, D, Lemus, J, Fernandez, Rl, Jaramillo, C, Ochoa, J, Velez, S, Cano, N, Lutz, J, Botero, R, Jaramillo, M, Saaib, J, Sanchez, G, Hernandez, H, Mendoza, F, Rizcala, A, Urina, M, Polasek, R, Motovska, Z, Zemanek, D, Ostransky, J, Kettner, J, Spinar, J, Groch, L, Ramik, C, Stumar, J, Linhart, A, Pleva, L, Niedobova, E, Macha, J, Vojacek, J, Stipal, R, Galatius, S, Eggert, S, Mickley, H, Egstrup, K, Pedersen, O, Hvilsted, L, Sykulski, R, Skagen, K, Dodt, K, Klarlund, K, Husted, S, Jensen, G, Melchior, T, Sjoel, A, Steffensen, Fh, Airaksinen, Ke, Laukkanen, Ja, Syvanne, Ms, Kotila, Mj, Mikael, K, Naveri, Hk, Hekkala, Am, Mustonen, Jn, Halkosaari, M, Ohlmann, P, Khalife, K, Dibon, O, Hirsch, Jl, Furber, A, Nguyen-Khac, Jo, Delarche, N, Probst, V, Lim, P, Bayet, G, Dauphin, R, Levai, L, Galinier, M, Belhassane, A, Wiedemann, Jy, Fouche, R, Coisne, D, Henry, P, Schiele, F, Boueri, Z, Vaquette, B, Davy, Jm, Cottin, Y, D'Houdain, F, Danchin, N, Cassat, C, Messner, P, Elbaz, M, Coste, P, Zemour, G, Maupas, E, Feldman, L, Soto, Fx, Ferrari, E, Haltern, G, Heuer, H, Genth-Zotz, S, Loges, C, Stellbrink, C, Terres, W, Ferrar, M, Zeymer, U, Brachmann, J, Mudra, H, Vohringer, Hf, vom Dah, J, Kreuzer, J, Hill, S, Kleinertz, K, Kadel, C, Appel, Kf, Nienabe, C, Behrens, S, Frantz, S, Mehrhof, F, Krings, P, Hengstenberg, C, Lueders, S, Hanefel, C, Krulls-Munch, J, Dorse, T, Leschke, M, Nogai, K, Butter, C, Darius, H, Fichtlscherer, Hp, Schmitt, C, Kasisk, Hp, Dorr, M, Fran, N, Jereczek, M, Wiemer, M, Nickenig, G, Boudriot, E, Werner, G, Altila, T, Strasser, R, Baldus, S, Desaga, M, Buerke, M, Land, S, Schunkert, H, Schulze, Ho, Holmer, S, Sohn, Hy, Burkhardt, W, Lauer, B, Schwimmbeck, P, Schoeller, R, Lapp, H, Gross, M, Kindermann, I, Schuster, P, Yu, Cm, Lee, S, Merkely, B, Apro, D, Lupkovics, G, Edes, I, Ungi, I, Piroth, Z, Csapo, K, Dezsi, Ca, Herczeg, B, Sereg, M, Butnaru, A, Lewis, B, Rosenschein, U, Mosseri, M, Turgeman, Y, Pollak, A, Shotan, A, Hammerman, H, Rozenman, Y, Gottlieb, S, Atar, S, Weiss, A, Marmor, A, Iakobishvili, Z, Mascia, F, De Cesare, N, Piovaccari, G, Ceravolo, R, Fiscella, A, Salvioni, A, Silvestri, O, Moretti, L, Severi, S, Carmina, Mg, De Caterina, R, Fattore, L, Terrosu, P, Trimarco, B, Ardissino, D, Uguccioni, L, Auguadro, C, Gregorio, G, De Ferrari, G, Testa, R, Evola, R, De Servi, S, Sganzerla, P, Vassanelli, C, Brunelli, C, Scherillo, M, Tamburino, C, Limido, A, Luzza, F, Percoco, Gf, Sinagra, G, Volpe, M, Crea, F, Fedele, F, Rasetti, G, Cinelli, F, Merlini, P, Sisto, F, Biancoli, S, Fresco, C, Corrada, E, Casolo, G, Santini, M, D'Alessandro, B, Antoniucci, D, Tuccillo, B, Assennato, P, Puccioni, E, Pasquetto, G, Perna, Gp, Morgagni, G, Takizawa, K, Kato, K, Oshima, S, Yagi, M, Asai, T, Kamiya, H, Hirokami, M, Sakota, S, Sueyoshi, A, Shimomura, H, Hashimoto, T, Miyahara, M, Matsumura, T, Nakao, K, Kakuta, T, Nakamura, S, Nishi, Y, Kawajiri, K, Nagai, Y, Takahashi, A, Ikari, Y, Hara, K, Koga, T, Fujii, K, Tobaru, T, Tsunoda, R, Uchiyama, T, Hirayama, H, Fujimoto, K, Sakurai, S, Tanigawa, T, Ohno, M, Yamamoto, E, Ikuta, S, Kato, A, Kikuta, K, Takami, A, Chong, Wp, Ong, Tk, Yusof, A, Maskon, O, Kahar, A, Breedveld, Rw, Bendermacher, Pe, Hamer, Bj, Oude Ophuis AJ, Nierop, Pr, Westendorp, Ic, Beijerbacht, Hp, Herrman, Jp, van 't Hof AW, Troquay, Rp, van der Meer, P, Peters, Rh, van Rossum, P, Liem, A, Pieterse, Mg, van Eck JW, van der Zwaan, C, Pasupati, S, Elliott, J, Tisch, J, Hart, H, Luke, R, Scott, D, Ternouth, I, White, H, Hamer, A, Harding, S, Wilkins, G, O'Meeghan, T, Harrison, N, Nilsen, D, Thalamus, J, Aaberge, L, Brunvand, H, Lutterbey, G, Omland, Tm, Eritsland, J, Wiseth, R, Aase, O, Campos, C, Horna, M, Toce, L, Salazar, M, Przewlocki, T, Ponikowski, P, Kasprzak, J, Kopaczewski, J, Musial, W, Mazurek, W, Kawecka-Jaszcz, K, Pluta, W, Dobrzycki, S, Loboz-Grudzien, K, Lewczuk, J, Karwowski, D, Grajek, S, Dudek, D, Trusz-Gluza, M, Kornacewicz-Jach, Z, Gil, R, Ferreira, J, Gavina, C, Ferreira, R, Martins, D, Garcia-Rinaldi, R, Ufret, R, Vazquez-Tanus, J, Banchs, H, Wong, A, Tan, Hc, Guerra, M, Ebrahim, I, Roux, J, Blomerus, P, Saaiman, A, Corbett, C, Pillay, T, Freeman, V, Horak, A, Zambakides, C, Burgess, L, Yoon, Jh, Ahn, Th, Gwon, Hc, Seong, Iw, Kim, Hs, Jeong, Mh, Kim, Yd, Chae, Sc, Hernandez, Jm, Pique, M, Fernandez Portales, J, Paz, Ma, Lopez Palop, R, Iniguez, A, Diaz Fernandez, J, Alvarez, P, Sanz, E, Heras, M, Sala, J, Goicolea, J, Cruz Fernandez, J, Serra, A, Fernandez Ortiz, A, Calle, G, Barriales, V, Albarran, A, Curos, A, Molano Casimiro FJ, Suarez, Ma, Franco, Sn, Bayon, J, Suarez, J, Belchi, J, Moreu, J, San Martin, M, Melgares Moreno, R, Aguirre Salcedo, J, Gonzalez Juanatey JR, Martinez Romero, P, Galache Osuna JG, Albertsson, P, Diderholm, E, Lycksell, M, Rasmanis, G, Swahn, E, Cherfan, P, Christensen, K, Lundman, P, Larson, Le, Vasko, P, Pripp, Cm, Johansson, A, Moccetti, T, Corti, R, Pieper, M, Mach, F, Eberli, F, Jeger, R, Rickli, H, Vogt, P, Windecker, S, Wu, Cj, Kao, Hl, Charng, Mj, Chang, Kc, Chen, Zc, Tsa, Cd, Shyu, Kg, Lai, Wt, Hsieh, Ic, Hou, Jy, Yeh, Hi, Ueng, Kc, Yin, Wh, Timurkaynak, T, Yigit, Z, Yilmaz, M, Boyaci, A, Sahin, M, Goktekin, O, Bozkurt, E, Ercan, E, Yildirir, A, Muthusamy, R, Keeling, P, Levy, T, Zaman, A, Cohen, A, Gorog, D, Baumbach, A, Oldroyd, K, Kadr, H, Tait, G, Bellenger, N, Davis, G, Shakespeare, C, Senior, R, Bruce, D, Uren, N, Trouton, T, Ahsan, A, Hamed, A, Malik, I, Sarma, J, Millar-Craig, M, Robson, H, Kennon, S, Sprigings, D, Brodie, B, Kang, Gs, Thomas, G, Cheng, Sc, Espinoza, A, Kassas, S, Jafar, Z, Kumar, P, Izzo, M, Wiseman, A, Chandna, H, Felten, W, D'Urso, M, Gudipati, Cr, Coram, R, Gill, S, Bengtson, J, Chang, M, Raisinghani, A, Blankenship, J, Harbor, Wf, Kraft, P, Ashraf, R, Chambers, J, Albirini, A, Malik, A, Ziada, K, Slepian, M, Taussig, A, Vernon, H, Jetty, P, Islam, Ma, Canaday, D, Martin, T, Burchenal, Jj, Gencheff, N, Nygaard, T, Panchal, V, Merritt, R, Abrahams, L, Lambert, C, Reyes, P, Leimbach, W, Chhabra, A, Caputo, R, Imburgia, M, Erickson, B, Kleiman, N, Hunter, J, Dehning, M, Graham, B, Strain, J, White, Jk, Mcgarvey, J Jr, Henderson, D, Treasure, C 2nd, Mirro, M, Pancholy, S, Helmy, T, Westerhausen, D, Dib, N, Penny, W, Kim, H, Degregorio, M, Jay, D, Kmonicek, J, Berlowitz, M, Starling, M, Langevin, E, Nelson, R, Singer, A, Siachos, A, Gibson, G, Parrott, C, Held, J, Puleo, P, Wolford, T, Omar, B, Brilakis, E, Lewis, S, Heller, L, Brener, S, Addo, T, Lieberman, S, Eisenberg, D, Feldman, R, Waksman, R, Waltman, J, Schulman, S, Bounds, C, Voyce, S, Batchelor, W, Dobies, D, Pasnoori, V, Chandrashekhar, Y, Vetrovec, G, Azrin, M, Spriggs, D, Hirsch, C, Smucker, M, Chetcuti, S, Stella, R, Levite, H, Shoukfeh, M, Vidovich, M, Saucedo, J, Fintel, D, Low, R, Gellman, J, Ahsan, C, Unks, Dm, Tolleson, T, Ceccoli, H, Aggarwal, K, Bhaktaram, V, Olson, C, Decaro, M, Kaluski, E, Mehta, V, Puma, J, Singh, V, Fulmer, J, Lewis, D, Khadra, S, Staniloae, C, East, M, Sundram, Ps, Anderson, J, Wasserman, H, Guy, D, Brill, D, Kruse, K, Ebrahimi, R, Nguyen, T, Keating, F, Srivastava, R, Wassmer, P, Todd, J 3rd, Stein, M, Hamzeh, I, Laxson, D, Hodson, R, Puri, S, Vijayaraghavan, K, Gazmuri, R, Chu, A, Vijay, N, Rabinowitz, A, Block, T, Agarwal, H, Martin, J, Zetterlund, P, Fortuin, D, Macdonell, A 3rd, Zouzoulas, S, Chepuri, V, Schmalfuss, C, Karve, M, Aviles, R, Lieberman, E, Amlani, M, Murphy, S, Shapiro, T, Herzog, E, Ariani, K, Bhagwat, R, Hockstad, E, Kai, W, Saririan, M, Roth, R, Weiland, F, Atassi, K, Harjai, K, Muhlestein, J, Marsh, R, Shokooh, S, Nahhas, A, Labroo, A, Mayor, M, Koshy, S, Tariq, M, Rayos, G, Jones, S, Klugherz, B, Dewey, R, Rashid, Hu, Wohns, D, Feiring, A, Bowles, M, Rohrbeck, S, Monroe, Vs, De Gottlieb, A, Gumm, D, Brown, C 3rd, Chang, D, Kalaria, V, Minisi, A, Joumaa, M, Josephson, R, Kleczka, J, Silver, K, Coleman, P, Brachfeld, C, Saltiel, F, Reiner, J, Carell, E, Hanovich, G, Rosenberg, M, Das, G, Blick, D, and Universitat de Barcelona
- Subjects
Male ,Pyridines ,medicine.medical_treatment ,Kaplan-Meier Estimate ,law.invention ,Lactones ,Randomized controlled trial ,law ,Thrombin receptor antagonist ,clopidogrel ,placebo ,thienopyridine derivative ,vorapaxar ,antithrombocytic agent ,lactone ,proteinase activated receptor 1 ,pyridine derivative ,Coronary Artery Bypass ,Vorapaxar ,Cardiovascular diseases [NCEBP 14] ,Drugs ,General Medicine ,Middle Aged ,Combined Modality Therapy ,Cardiovascular diseases ,Cardiovascular Diseases ,Cardiology ,Platelet aggregation inhibitor ,Drug Therapy, Combination ,Female ,Plaquetes sanguínies ,Intracranial Hemorrhages ,Major bleeding ,Medicaments ,medicine.drug ,medicine.medical_specialty ,Acute coronary syndrome ,Bypass cardiopulmonary ,Hemorrhage ,Pharmacotherapy ,Blood platelets ,Double-Blind Method ,Angioplasty ,Internal medicine ,medicine ,Humans ,Receptor, PAR-1 ,Acute Coronary Syndrome ,Aged ,business.industry ,Malalties cardiovasculars ,medicine.disease ,Surgery ,Bypass cardiopulmonar ,business ,Platelet Aggregation Inhibitors ,Follow-Up Studies - Abstract
Item does not contain fulltext BACKGROUND: Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. METHODS: In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. RESULTS: Follow-up in the trial was terminated early after a safety review. After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo (Kaplan-Meier 2-year rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P=0.07). A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients in the vorapaxar group versus 910 in the placebo group (14.7% and 16.4%, respectively; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P=0.02). Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P
- Published
- 2012
- Full Text
- View/download PDF
50. Modelling the Impact of Atherosclerosis on Drug Release and Distribution from Coronary Stents
- Author
-
McKittrick, C. M., primary, Kennedy, S., additional, Oldroyd, K. G., additional, McGinty, S., additional, and McCormick, C., additional
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.